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ABSTRACT OF DISSERTATION 
 
 
ATTENUATING TRIGEMINAL NEUROPATHIC PAIN BY REPURPOSING 
PIOGLITAZONE AND D-CYCLOSERINE IN THE NOVEL TRIGEMINAL 
INFLAMMATORY COMPRESSION MOUSE MODEL 
 
Approximately 22% of the United States population suffers from a chronic 
orofacial pain condition.  One such condition is known as trigeminal neuropathic 
pain frequently reported as continuous aching and burning pain, often 
accompanied by intermittent electrical shock-like sensations. Dental procedures 
or trauma are known causes of peripheral trigeminal nerve injury and 
inflammation. Patients who have this type of facial pain also suffer from 
emotional distress. For these reasons, trigeminal neuropathic pain needs to be 
studied in more detail to improve the understanding of the etiology and 
maintenance of this condition, as well as to develop effective treatment 
strategies. The first experiment was focused on characterizing the behavioral 
aspects of the Trigeminal Inflammatory Compression (TIC) mouse model.  The 
findings determined that the TIC injury model induced mechanical and cold 
hypersensitivity that persist at least 21 weeks. This orofacial, neuropathic pain 
condition was accompanied by anxiety- and depressive-like behaviors at week 8 
post injury.  The TIC injury mouse model’s chronicity and development of 
psychosocial impairments demonstrated its usefulness as a facial pain model. 
The second experiment used the mouse TIC injury model to test the ability of 
pioglitazone (PIO), a PPARγ agonist used clinically for treatment of diabetes, on 
alleviating trigeminal pain.  A single low dose of PIO had no effect, but a higher 
dose attenuated facial pain. The third experiment determined that combining 
ineffective low doses of PIO and D-cycloserine (DCS) produced a potentiated 
anti-allodynic response of these drugs and attenuated the anxiety associated 
with the TIC injury. Ex vivo studies revealed that cortical mitochondrial 
dysfunction occurred after the TIC injury but could be reversed by the 
combination of DCS/PIO which improves mitochondrial function. Overall, the 
present studies determined that the novel mouse TIC injury model is a clinically 
relevant facial neuropathic pain model. The results suggest that PPARγ and 
brain mitochondria may represent new molecular targets for the treatment of 
trigeminal neuropathic pain. These studies support the future “repurposing” of 
 PIO and DCS as well as the combination of the two drugs for this new use in 
patients with trigeminal neuropathic pain.  
 
 
KEYWORDS: trigeminal inflammatory compression, mouse model,  
PPARγ, D-cycloserine, mitochondria  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Danielle N. Lyons 
December 3, 2014 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
ATTENUATING TRIGEMINAL NEUROPATHIC PAIN BY REPURPOSING 
PIOGLITAZONE AND D-CYCLOSERINE IN THE NOVEL TRIGEMINAL 
INFLAMMATORY COMPRESSION MOUSE MODEL 
 
 
By 
 
Danielle Nicole Lyons 
 
 
 
 
 
 
 
 
 
 
 
 
Dr. Karin N. Westlund High 
Director of Dissertation 
 
Dr. Bret N. Smith 
Director of Graduate Studies 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This dissertation is dedicated to my Rock and my Redeemer, my Lord and 
my Savior, Jesus Christ... 
 
“Let all that I am praise the Lord; may I never forget the good things He 
does for me.”- Psalm 103:2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ACKNOWLEDGEMENTS 
 
First of all, I have to thank my mentor, Dr. Karin Westlund High.  Thank you for 
the funding that you have provided me for this project. Thank you also for 
allowing me freedom to research what I wanted.  You trusted me and believed in 
my vision, so thank you.  I admire your courage in life and respect the passion 
you have for research.  I cannot thank you enough for all the time you have 
invested into me.  I will never forget all of your encouragement and support 
through my comprehensive exams as well as this dissertation process.  
Secondly, I have to thank everyone in the High lab that has been a great support 
to me. Liping, thank you for teaching me proper pharmacology and animal 
behavioral methods. Thank you also so much for the suggestions/revisions to 
this dissertation and the many times you have helped me with my experiments. 
You have been my constant companion and dear friend through this entire 
process. I thank you so much for the guidance, loyalty, and listening ear you 
have provided. Fei, thank you for teaching me your wonderful surgery techniques 
on the mice and rats. Thank you so much for all your support and suggestions on 
many other projects. Your input and smile has always made my day easier. Bob, 
thank you so much for teaching me how to immunostain and having a wonderful 
gracious attitude.  Sabrina, thank you for your many suggestions and useful 
input. Tracey, you are and forever will be my “partner in crime.” From testing all 
day on weekends to singing in the stairwell, our therapy sessions truly have been 
some of the best memories I have had in graduate school.  And to all of the past 
of rotating lab members and students, thank you for any help you provided. 
 
I would also like to thank my committee members.  Dr. Taylor, thank you for 
allowing me to rotate in your lab year one.  I learned so much from that 8 week 
rotation.  Thank you for always challenging me and pushing me to be the best 
that I can be. Dr. Frolenkov, thank you for your constant belief in me and my 
abilities.  Our scientific and non-scientific conversations have been such an 
encouragement.  Dr. Gerhardt, thank you so much for all of the knowledge you 
have provided about current literature and neuroscience.  Your ability to keep me 
focused has helped tremendously along with your positive and diplomatic 
attitude.   Dr. De Leeuw, thank you so much for allowing me to sit in on the 
Orofacial Pain Seminars and all of the input you have provided from the clinical 
perspective of orofacial pain.  You all have been amazing in availability to me 
and for that, I cannot thank you enough. 
 
I would like to extend a BIG THANK YOU to the department of Physiology as well 
as the University of Kentucky for funding me my first two years.  Thank you so 
much to my fellow grad students and friends who have been there to enjoy this 
journey with me. Thank you so much Sherry and Cindy, my “big sisters” who 
have made this department so much fun and have been there to celebrate every 
moment with me.  Thank you to Drs. Frolenkov and Campbell for the 
Communication Skills workshop and PGY 774.  Your investment in students is 
admirable and appreciated.  Thank you to Drs. Randall and Speck for being 
iv 
 
amazing teaching mentors.  I have learned so much from the both of you and 
love you dearly.  Thank you to Dr. Saatman for all your support during PGY 602- 
your kindness will never be forgotten.  Thank you to all of the faculty and 
professors who have invested their time to teach me physiology.  When I think of 
you all, it will be fondly. 
 
Thank you so much to the Taylor lab. Renee and Suzanne, you both have been 
my partners in crime and I will never forget you. Thank you also to the Sullivan 
lab: Drs. Sullivan, Pandya, and Patel for their time and mentoring. 
 
Thank you so much to COBRE grant under Dr. Jeff Ebersole that supported 
some of the funding for this project.  I want to thank Drs. Danaher, Miller, and 
Carlson for all of your valued input and direction with these experiments. Thank 
you for your revisions/editions on several papers and for all the time you each 
invested.  Robert, thank you for always being willing to order what I needed.  
Your joy is remarkable and came just when I needed it so thank you. Dr. Miller, 
thank you for wise criticisms and positive comments.  You always pushed me to 
better explain myself- a tool that will no doubt help me in the future 
 
Thank you to my family.  You guys have seen me through every up and every 
down.  You always have my back and never withdrawal your love.  You guys 
remind me of the verse in Proverbs 31 when it states, “you are worth more than 
rubies.”   God overflowed my cup when He gave me all of you.  Thank you to my 
“fave”, Cameron.  I love you neph/bro!  Any time spent with you made me feel 
blessed.  Kenna, my lovely sister, thank you for all you give.  You love is awe-
striking and you are the best big sister a girl could ask for.  Connor, thank you for 
bringing life to our family.  Kerry, you will always be my favorite brother-in-law.  
 
To my parents, thank you for always being a phone call away. Thank you for 
always agreeing with even when if I was wrong. To my wonderful mother and 
best friend, you are the inspiration of this dissertation.  Any time I wanted to give 
up, it was the thought of you that would keep me going.  For you were right when 
you said, “Anything great, is worth fighting for.”  And you, Mommy, are definitely 
worth fighting for. Thank you to my steadfast father.  You reflect the Father’s love 
to me in such a pure way.  Thank you for our many golf outings and dinners that 
reset my battery.  Thank you so much for never getting tired of me “talking 
science.”  I love you both so much. 
 
Thank you to all my friends who have been there to pray with me and listen to 
me.  Thank you for your constant support through this process.  There are too 
many to name, but I love you all dearly. 
 
Lastly, thanks be to God.  Who gave me rest when I needed it, and strength 
when I could not go on.  “To our God and Father be glory for ever and ever. 
Amen.”  -Philippians 4:20 
 
v 
 
TABLE OF CONTENTS 
 
Acknowledgements         iii 
List of Tables         ix 
List of Figures         x 
 
1 Chapter 1: Introduction and Background 
1.1   Introduction of Continuous Trigeminal Neuropathic Pain 1 
1.2   Anatomy of the Trigeminal System    5 
1.3   Biopsychosocial Model of Pain      8 
1.4   Current Treatments       9 
1.5   Trigeminal Inflammatory Compression (TIC) Injury  11 
1.6   Scope and Hypothesis of the Dissertation   13 
 
2 Chapter 2: Induced Facial Pain, Anxiety-and Depression Related  
Behaviors Associated with Trigeminal Inflammatory Compression  
(TIC) Injury          
2.1 Introduction          23 
2.2 Materials and Methods        26 
2.2.1 Animals        26 
2.2.2 Trigeminal Inflammatory Compression (TIC) Injury Surgery 26 
2.2.3 Behavioral Tests       27 
2.2.3.1 Assessment of Mechanical Allodynia   28 
2.2.3.2 Assessment of Thermal Hypersensitivity   29 
2.2.3.3 Acoustic Startle Disturbance    30 
2.2.3.4 Two Compartment Light-Dark Box Preference Test 31 
2.2.3.5 Open Field Exploratory Activities    32 
2.2.3.6 Elevated Plus Maze Task     33 
2.2.4 Statistical Analysis       34 
2.3 Results         34 
2.3.1 Animals with TIC Injury Displayed Unilateral  Whisker Pads 
Mechanical Allodynia      34 
2.3.2 TIC Injury Induced a Unilateral Cold Allodynia of the V2  
Area         36 
2.3.3 Animals with TIC Injury Displayed Anxiety- and  
Depressive-Like Behaviors in Two Compartment Light-Dark 
Preference Testing       37 
2.3.4 Acoustic Disturbance Affected Mice with TIC in the Elevated      
Plus Maze Task       38 
2.3.5 Mice with TIC Injury Showed Less Exploratory Activities 39 
2.4 Discussion          39 
2.4.1 TIC Injury Model Mimics Clinical Facial Neuropathic Pain 39 
2.4.2 TIC Injury Developed Anxiety- and Depressive -Like Behaviors 
Similar to Patients Suffering with Chronic Facial Pain  41 
vi 
 
2.4.3 Decreased Fear Response in Mice with TIC after Acoustic 
Disturbance        44 
2.5 Conclusion         47 
 
 
3 Chapter 3: Rapid Effects of PPAR-Agonists on Alleviation of  
Trigeminal Pain 
3.1 Introduction         57 
3.2 Materials and Methods       60 
3.2.1 Animals        60 
3.2.2 Trigeminal Inflammatory Compression (TIC) Surgery  60 
3.2.3 Assessment of Mechanical Allodynia on the Mouse Whisker  
Pad          60 
3.2.4 Immunohistological Study      60 
3.2.5 Image Analysis       62 
3.2.6 Drug Preparation and Administration    62 
3.2.7 Statistical Analysis       64 
3.3 Results          65 
3.3.1 Mice with TIC Injury Demonstrated Unilateral Whisker Pad 
Mechanical Allodynia      65 
3.3.2 The Effect of PPAR Agonists on Mechanical Allodynia of  
Mice with TIC Injury       66 
3.3.2.1 PPARγ Agonist, Pioglitazone, Attenuated Mechanical 
Allodynia in Mice with TIC Injury    66 
3.3.2.2 PPARβ/δ Agonist Moderately Attenuated Mechanical  
Allodynia in the Mice with TIC Injury   67 
3.3.2.3 PPARα Agonist Had No Effect on the Mice with TIC  
Injury        67  
3.3.2.4 PPARγ Antagonist, GW9662, Blocked Analgesic 
 Effects of Pioglitazone     68 
3.3.3 PPARγ Was More Immunoreactive in the TBSNC of Mice  
with TIC injury       68 
3.4 Discussion         70 
3.5 Conclusion         74 
 
4 Chapter 4: Low-Dose Combination of Pioglitazone and D-Cycloserine 
Attenuated Orofacial Pain by Improving Mitochondrial Dysfunction 
4.1 Introduction         83 
4.2 Materials and Methods       88 
4.2.1 Animals        88 
4.2.2 Trigeminal Inflammatory Compression (TIC) Injury  88 
4.2.3 Behavioral Assays       88 
4.2.3.1 Detecting Mechanical Allodynia with von Frey Fiber  
Test         88 
vii 
 
4.2.3.2 Light-Dark Box Preference Testing   89 
4.2.4 Drug Preparation and Administration    89 
4.2.4.1 Drug Preparation      89 
4.2.4.2 Drug Administration      89 
4.2.4.2.1 Experiment 1: Treatment of Mechanical  
Allodynia with NMDA Receptor Agonist/ 
Antagonist, DCS      90 
4.2.4.2.2 Experiment 2: One-time Injection of  
Combination of DCS/PIO    91 
4.2.4.2.3 Experiment 3: 7-day Treatment of 80 mg/kg  
Dose of DCS Followed by a Bolus of  
100 mg/kg Dose of PIO on the 7th Day  91 
4.2.4.2.4 Experiment 4: Single Dose of Mitochondrial  
Uncoupler 2,4-DNP     92 
4.2.5 Mitochondrial Isolation Assays     92 
4.2.5.1 Isolated Mitochondria Preparation   92 
4.2.5.2 Bioscience Seahorse XFe24 Flux Analyzer Assay 93 
4.2.6 Statistical Analysis       95 
4.3 Results         96 
4.3.1 Unilateral Facial Mechanical Allodynia in Mice with TIC  
Injury          96 
4.3.2 D-cycloserine Attenuated Mechanical Allodynia But Did  
Not Relieve Anxiety Behaviors Associated with 
Hypersensitivity       97 
4.3.3 Attenuation of Mechanical Alloydnia and Anxiety by  
Combination of Ineffective Low Doses of D-cycloserine  
and Pioglitazone       98 
4.3.4 2.4-DNP Attenuated Mechanical Allodynia in Mice with TIC  
Injury         100 
4.3.5 Cortex Mitochondria Had a Decreased Respiratory  
Control Ratio in Mice with TIC Indicating Cortical  
Mitochondrial Dysfunction      100 
4.3.6 Drug Combination Treatment Increased Respiratory  
Control Ratio in Brainstem Mitochondria of Mice with 
TIC Injury        102 
4.4 Discussion         102 
4.5 Conclusion         108 
 
5 Chapter 5: Overall Discussion and Conclusions 
5.1 Trigeminal Inflammatory Compression (TIC) Injury is a Clinically  
Relevant Orofacial Neuropathic Pain Model    119 
5.2 PPARγ is an Important Molecular Target for the Treatment  
of Trigeminal Neuropathic Pain      121 
5.3 Mitochondrial Dysfunction is One Underlying Mechanism of  
Trigeminal Neuropathic pain      123 
5.4 Limitations and Future Studies      124 
viii 
 
5.5 Significance and Innovation      130 
5.6 Conclusion         134 
 
Appendices 
Appendix 1. Abbreviations        135 
 
References          138 
 
Vita           155  
 
 
 
 
  
ix 
 
LIST OF TABLES 
 
 
1.1 Chronic Pain Is More Prevalent Than Other Major Diseases   16 
2.1 Light-Dark Box Data         48 
2.2 Elevated Plus Maze Data         49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
x 
 
LIST OF FIGURES 
 
1.1 Anatomy of Trigeminal Nerve       17 
1.2 Trigeminal Brainstem Sensory Nuclear Complex (TBSNC) with  
Specific Nociceptor Fiber Representation      18 
1.3 Functional Magnetic Resonance Imaging (fMRI) of a Patient  
Suffering from Trigeminal Neuropathic Pain     19 
1.4 The Matrix of “Pain Sensation” and “Pain Affect.”     20 
1.5 The Trigeminal Sensory System in Rodents    21 
1.6 The CCI-ION Injury Model in Rats Compared to the TIC Injury Model in  
Mice          22  
2.1 TIC Injury Induced Mechanical and Cold Allodynia    50 
2.2 Mice with TIC Injury Had Anxiety- and Depressive-Like Behavior in the 
Light-Dark Box         52 
2.3 Acoustic Disturbance Affected Mice with TIC Injury in Elevated  
Plus Maze          53 
2.4 Mice with TIC Injury Showed Decreased Exploratory Activity  
in Open Field          55 
3.1 Mice with TIC Injury Developed Unilateral Mechanical Allodynia on  
the Ipsilateral Whisker Pad       75 
3.2 Pioglitazone (PIO) Attenuated Mechanical Allodynia in the Mice  
with TIC Injury         76 
3.3 PPARγ Immunoreactivity Increased in TBSNC of the Mice with TIC          
Injury          78 
3.4 PPARγ  Immunoreactivity Localized Throughout the Trigeminal  
Brainstem Sensory Nuclear Complex in Mice with TIC Injury  80 
3.5 PPARγ Immunoreactivity at the Spinal Trigeminal Nucleus  
Interpolaris in Sham Mice vs. Mice with TIC Injury    82 
4.1 TIC Injury Induced Unilateral Whisker Pad Mechanical Allodynia  109 
4.2 DCS Attenuated Mechanical Allodynia, but Does Not Reverse  
Anxiety-Like Behavior in the Mice with TIC Injury     110 
4.3 The Combination of DCS and PIO Attenuated Mechanical Allodynia  
and Anxiety-Like Behavior in the Mice with TIC Injury    112 
4.4 A Mild Mitochondrial Uncoupler Attenuated the Mechanical Allodynia  
in the Mice with TIC Injury        114 
4.5 Isolated Cortical Mitochondria from the Mice with TIC Injury Showed an 
Increased State III and State IV OCR, but Decreased RCR which is    
Reversed with the Drug Combination of DCS + PIO    115 
4.6 The Drug Combination (DCS +PIO) Increased the Brainstem  
Mitochondrial RCR in the Mice with TIC Injury     117 
 
 
 
1 
 
CHAPTER ONE 
INTRODUCTION AND BACKGROUND   
 
1.1 . Introduction of Continuous Trigeminal Neuropathic Pain 
Aristotle believed that pain along with all other sensations e.g. vision/taste 
were perceived in the heart (Chen 2011; Rey 1993). For a culture in the prime of 
the dramatic theatre, where masks were used to describe an actor’s emotion, 
perhaps Aristotle and his fellow philosophers at the time thought that “emotions” 
were revealed in face, but felt in the heart. However, in the 1500s, autopsies 
performed by Andreas Vesalius supported the theory that the brain was in fact 
the site of perception of all sensations including pain. In the 1600s, René 
Descartes, the “Father of Modern Philosophy,” reasoned that peripheral sensory 
nerve fibers carried the “pain” signal to the spinal cord. The signal was then 
thought to be transmitted to the brain along neurons and then to the pineal organ 
(Descartes’ believed site of pain perception) (Chen 2011; Rey 1993). In 1664, 
Thomas Willis published the Cerebri Anatome which reinforced the brain as the 
site of pain and the cerebral cortex as the key player in pain perception. Since his 
discovery, countless scientists have added to the anatomy and theory of pain 
perception in hopes of answering two major questions: 1) What is pain? and 2) 
How can pain be stopped?   
Although these questions are still being pursued, previous studies have allowed 
the International Study of Pain (IASP) to form a solid definition:  
 
“Pain is an unpleasant sensory and emotional 
experience associated with actual or potential 
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tissue damage, or described in terms of such 
damage.” (IASP 2014)  
 
However, this definition barely begins to describe the mechanisms of pain or the 
many different types of pain that exist. For example, allodynia is specific “pain 
due to stimulus that does not normally provoke pain” while hyperalgesia is 
“increased pain from a stimulus that normally provokes pain” (IASP 2014). The 
American Academy of Pain Medicine provides a good definition of chronic pain,  
 
“Pain that persists due to pain signals 
continuing to fire in the nervous system for 
weeks, months, even years (pain resulting from 
damage to the peripheral nerves or central 
nervous system.” (AAPM, 2014) 
 
 
Generally, pain is considered chronic if it lasts longer than 3 months. 
Surprisingly, 100 million American citizens suffer from some form of chronic pain 
(AAPM 2014). Table 1.1 shows that patients with chronic pain are four times 
more prevalent in the population than patients with diabetes as well as patients 
suffering from heart disease/stroke (AAPM 2014). These statistics are most likely 
due to the fact that in every disease “damage” occurs in the infected tissue often 
times eliciting a painful response. Hence if a person has a chronic disease, then 
they could also suffer from chronic pain. Due to the numerous chronic diseases, 
there are multiple classifications of chronic pain including chronic neuropathic 
pain. According to IASP, neuropathic pain is defined as 
 
“Pain caused by a lesion or disease of the 
somatosensory nervous system. 
3 
 
 
Note: Neuropathic pain is a clinical description 
(and not a diagnosis) which requires a 
demonstrable lesion or a disease that satisfies 
established neurological diagnostic criteria. The 
term lesion is commonly used when diagnostic 
investigations (e.g. imaging, neurophysiology, 
biopsies and laboratory tests) reveal an 
abnormality or when there was obvious trauma. 
The term disease is commonly used when the 
underlying cause of the lesion is known (e.g. 
stroke, vasculitis, DIABETES MELLITUS, 
genetic abnormality). Somatosensory refers to 
information about the body per se including 
visceral organs, rather than information about 
the external world (e.g., vision, hearing, or 
olfaction). The presence of symptoms or signs 
(e.g., touch-evoked pain) alone does not justify 
the use of the term neuropathic. Some disease 
entities, such as TRIGEMINAL NEURALGIA, 
are currently defined by their clinical 
presentation rather than by objective diagnostic 
testing. Other diagnoses such as postherpetic 
neuralgia are normally based upon the history. 
It is common when investigating neuropathic 
pain that diagnostic testing may yield 
inconclusive or even inconsistent data. In such 
instances, clinical judgment is required to 
reduce the totality of findings in a patient into 
one putative diagnosis or concise group of 
diagnoses.” (IASP 2014) 
 
The note in the IASP definition describes neuropathic pain as a “clinical 
description” because of the difficulties in diagnosing patients with neuropathic 
pain when no cause of the pain is currently known or observed. Interestingly 
enough, at least half of the note description was referring to orofacial pain 
defined as “pain and dysfunction affecting motor and sensory transmission in the 
trigeminal nerve system” (De Leeuw 2008).  
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Trigeminal neuropathic pain was first alluded to by Areataues of 
Cappadocia in the 2nd Century. He not only described migraines, but also 
described “facial spasms and distortions of the countenance” (Nurmikko & 
Eldridge 2001). In 1756, Nicolaus André coined the term “tic douloureux,” 
meaning painful twitch, to describe these facial spasms currently known today as 
Trigeminal Neuralgia. However, it was not until 1773 when a full account of 
trigeminal neuralgia was published by John Fothergill. Although trigeminal 
neuralgia is the most well-known of the trigeminal neuropathic pain conditions, 
modern day diagnosis has helped better classify the different types of trigeminal 
neuropathic pain in order to determine proper treatment.   
Zakrzweska and colleagues (2013) depicts the most recent classifications 
of chronic neuropathic facial disorders using the following features to categorize 
the pain : 1) location, 2) timing, 3) quality severity, 4) aggravating factors, 5) 
associated factors, 6) examination 7) investigations (scans or sensory testing), 
and 8) pain management (Zakrzewska 2013). Trigeminal neuralgia, episodic 
chronic pain, is viewed separately from continuous trigeminal neuropathic pain 
that exists in the absence of the paroxysmal attacks. For clinicians, continuous 
trigeminal neuropathic pain can often times be the most difficult to treat because 
of the amount of peripheral and central factors that contribute to the exact cause 
of the pain (Blasberg & Greenberg 2008; De Leeuw 2008; Okeson 2005; 
Zakrzewska 2013). Even though the etiology of every syndrome cannot be 
defined, understanding the anatomy of the trigeminal system is certainly helpful 
in determining some problems with trigeminal pain transmission.  
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1.2 . Anatomy of the Trigeminal System  
The trigeminal nerve is the fifth cranial containing both a motor and 
sensory nuclei relaying information to and from the orofacial region. This largest 
cranial nerve consists of three main peripheral branches: ophthalmic (V1), the 
maxillary (V2), and the mandibular (V3). Figure 1.1 (De Leeuw 2008) depicts the 
specific orofacial region innervated by each main branch of the trigeminal nerve.  
The ophthalmic branch innervates the region comprised of the forehead and the 
upper 1/3 of the face, including the meninges. The maxillary innervation region is 
the middle 1/3 of the face below the eye encompassing the sinuses and the 
mouth region. The mandibular branch innervates the lower parts of mouth, 
mandible bone with the temporomandibular joint, and ear (De Leeuw 2008). 
The relay of neuronal transmission from the periphery for central 
perception begins with a stimulus activating the peripheral pseudo-unipolar 
sensory neurons. Noxious input is transduced by the primary afferent 
nociceptors. Nociceptors are located in the skin, viscera, joints, vasculature, and 
muscle, although they are typically silent in deep structures. With specificity in 
function, modality, and density, nociceptors are able to respond to any noxious 
heat, cold, mechanical, and chemical stimulus. The primary nociceptor subtypes 
relay their information via primary afferents which include: A-delta afferents, 
thinly myelinated fibers with a conduction velocity of > 2 m/s and C-fiber 
afferents, unmyelinated fibers with a slower conduction velocity <2 m/s (Wall & 
Melzack 1999; Westlund & Willis 2015; Willis & Westlund 1997). These two 
primary afferent axonal subtypes respond similarly to the nociceptive stimuli with 
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the exception that the A-delta fibers surpass the C fibers in firing rate and do not 
respond to chemical stimuli (Voscopoulos & Lema 2010; Wall & Melzack 1999). 
As compared to A-beta fibers, primary afferents that respond to low threshold 
mechanical stimuli, the C and A-delta nociceptors have a significantly higher 
activation threshold in order to respond with an action potential in “normal 
conditions.” Therefore, slight touch (a low threshold stimulus) across the face 
elicits firing in the A-beta fibers while a slap across the face (a mix of low and 
high threshold stimuli) elicits the firing of not only the A-beta fibers, but also the C 
and A-delta fibers to generate action potentials.  
These primary afferent neurons have their cell bodies in the peripheral 
trigeminal ganglion also known as the Gasserian ganglion, a collection of ganglia 
from all three branches of the trigeminal system. Together, the peripheral 
neurons enter the trigeminal dorsal root entry zone and may ascend/descend the 
brainstem to synapse at different levels of the trigeminal brainstem sensory 
nuclear complex (TBSNC) depicted in Figure 1 and 2. The nuclei composing the 
TBSNC are the main sensory nucleus and the spinal trigeminal nucleus (sp5), 
which is composed of three subnuclei: oralis, interpolaris, and caudalis. 
Figure1.2 (DaSilva & DosSantos 2012) shows the distribution of the A and C 
fibers. The A-beta fibers synapse primarily in the main sensory nucleus located in 
the pons and some in the sp5 oralis. The A-delta and C-fibers synapse onto 
second order neurons in the sp5 oralis, interporalis and sp5 caudalis, with the 
majority of the C-fibers synapsing in sp5 caudalis. 
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The second order neurons in the TBSCN ascend parallel with the medial 
lemniscus pathway, the sensory fibers arising from spinal levels. They project 
from the brainstem and synapse onto neurons in the ventroposteromedial (VPM) 
nucleus of the thalamus, “the sensory relay center,” forming what is known as the 
trigeminothalamic pathway. From the VPM the third order neurons in the 
thalamus will synapse onto postcentral gyrus neurons (somatosensory cortex), 
the actual site of pain perception. Figure 1.3 (Becerra et al 2006) depicts this 
pathway using fMRI BOLD imaging from a patient suffering from trigeminal 
neuropathic pain. When a specific noxious stimulus was applied to the facial 
region, all areas of the trigeminal system were highlighted implicating 
involvement of the entire system in chronic facial pain. 
However, the neurological system is extremely complicated involving 
many signaling pathways. The thalamus has received the title “the sensory relay 
center” because it not only receives input from the spinal trigeminal nucleus and 
then relays it to the cortex, but also receives input from all levels of the brainstem 
and the spinal cord and delivers their messages to the higher order areas of the 
brain. Figure1.4 (May 2009) illustrates the “pain matrix “thereby highlighting all 
the areas of the brain influencing pain perception (i.e. primary and secondary 
somatosensory cortex, insula cortex, prefrontal cortex, cingulate cortex, posterior 
parietal cortex, amygdala, thalamus, periaqueductal gray, basal ganglia, 
supplementary motor area, and the nucleus accumbens (not shown in the 
figure)). This would indicate and support the idea that pain processes are not 
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only just a response to a peripheral nociceptive input, but are also activation of a 
central network. 
 
1.3 . Biopsychosocial Model of Pain 
Wall and Melzack (1999) highlighted this feature of pain when they said 
pain can best be described in two aspects: “pain sensation” and “pain affect.” 
This is referring not only to the biological disturbance and emotional distress that 
a chronic pain patient experiences, but also including the disruptions in 
psychosocial functioning associated with this condition/syndrome  (Engel 1997; 
Quintner et al 2008; Wall & Melzack 1999).  
Perhaps Aristotle’s definition of pain perception occurring in the heart was 
not exactly wrong. Although physiologically incorrect, Aristotle understood the 
emotional aspect of pain that the philosophers in the 17th century overlooked. 
“Pain” does not exist in a vacuum and cannot exclusively be caused by one thing 
such as the historical biomedical model of pain suggests. This model illustrates a 
direct cause to the pain that a person perceives. It illustrates pain only as a 
symptom of an injury that occurred elsewhere in the body (Blasberg & Greenberg 
2008; De Leeuw 2008). However, not every painful syndrome appears to have a 
direct cause. Therefore, pain cannot solely be due to “sensation.” In 1977, 
George Engel coined the term “biopsychosocial model of illness” in which he 
challenged the biomedical model of “cause-and-effect” and begin describing 
illness as the interaction of the biological, psychological, social, and cultural 
components that are exposed to a person (Engel 1977). All of these factors play 
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a key role in a person’s perception and self-diagnosis of their pain (Quintner et al 
2008). 
Anxiety related to trigeminal neuropathic pain was first described by an 
Arab physician, Jujani, in the 11th century (Nurmikko & Eldridge 2001). Today, 
many patients with chronic trigeminal neuropathic pain also report numerous 
comorbid physical and psychological conditions as well as psychosocial and 
economic issues (i.e. medical expenses, loss of work, sleep disturbances, 
anxiety, depression, and family conflict) (Asmundson & Katz 2009; Burris et al 
2010; De Leeuw 2008; Nicholson & Verma 2004; Porto F 2011). Besides the 
anxiety and depression that are related to pain, some patients may often even 
experience cognitive impairment due to their pain. ((Ji et al 2010). Several 
studies have supported the amygdala, nucleus accumbens, and pre-frontal 
cortex, as major players in the observed emotional or cognitive effects (Apkarian 
2004; Apkarian et al 2004a; Apkarian et al 2004b; Ji et al 2010) . However, with 
the pain matrix being so interconnected, often times it is difficult to determine 
which higher order brain regions are solely responsible for the changes observed 
in the brain. Therefore, this makes treating the patients with chronic continuous 
trigeminal pain very difficult. 
 
1.4. Current Treatments 
 Clinicians have progressed in their ability to provide treatment for patients 
suffering from chronic orofacial pain. They are beginning to understand the 
comorbidities of this syndrome and therefore treat not only the “sensation,” but 
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also the “pain affect.” Pharmacological approaches along with psychological 
therapy have been implemented. 
 The first line of pharmacological treatment is purely based on the pain 
assessment and history of that patient. If local anesthetics fail to relieve pain, 
many studies show that tricyclic antidepressants such as amitriptyline, doxepin, 
or nortriptyline improve the pain of patients as well as their anxiety/depression 
related to their pain. Anticonvulsants, such as gabapentin, are typically not 
effective in subduing their pain (De Leeuw 2008). Still, pregabalin and tramadol 
have also been prescribed. However, many patients still struggle to find any 
medications that attenuate their pain. 
 To treat the “pain affect,” clinicians and therapist often adapt the 
biobehavioral model of therapy in order to treat patients suffering with chronic 
pain. Carlson (2008) states the biobehavioral approach as “integrating the 
important roles biological factors play in governing human function with the 
influences of behavioral factors” (Carlson 2008). Cognitive behavioral therapy 
(CBT) is one type of biobehavioral therapy that focuses on the patient becoming 
more self-aware or their condition in order to inhibit the external influences 
potentiating their pain response (Ehde et al 2014). The patient learns a new skill 
set to better disregard the outside reinforcement of the pain by learning tools for 
relaxation, routine management, self-care, and the self-awareness of external 
factors that potentiate their pain (Carlson 2008; Carlson et al 2001; Ehde et al 
2014; Ullrich et al 2013). 
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 Although somewhat effective, these therapies are still proving to be 
unsatisfactory in treating all patients with continuous trigeminal neuropathic pain 
(Koopman et al 2010). Therefore, a great need exists for new medications for 
these patients and a greater understanding about this type of neuropathic pain 
will better help to treat patients suffering with this type of continuous trigeminal 
neuropathic pain. It is for such reasons that animal models of chronic pain 
conditions such as trigeminal neuropathic pain need to be studied in more detail 
to better understand the etiology and maintenance of these conditions as well as 
to develop effective treatment strategies.   
 
1.5. Trigeminal Inflammatory Compression (TIC) Injury  
It is necessary for pre-clinical models to accurately represent the clinical 
picture of patients with trigeminal neuropathic pain in order to improve the validity 
of the results obtained from pre-clinical research. The rodent model has been 
chosen as the main model for inducing orofacial pain. One of the reasons for this 
is due to the fact that rodents are readily available as well as having a similar 
trigeminal system anatomy. Figure 1.5A depicts the rodent trigeminal system 
demonstrating the three main branches that correspond to the three main 
branches in humans (Leiser & Moxon 2006). Furthermore, it is quite easy to 
study the histology of the trigeminal brainstem sensory nuclear complex in a 
rodent because the barrel structure in the thalamus and brainstem corresponds 
to the whisker barrels on the whisker pad ((Erzurumlu et al 2006; Lee et al 
2009a; Lee et al 2009b; Li et al 1994; Negredo et al 2009; Zembrzycki et al 
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2013). Figure 1.5B (Mosconi et al 2010) illustrates the whisker barrels at the 
trigeminal dorsal horn, thalamus, and cortex in relation to the whisker pad.  
The historical model used to study trigeminal pain is the chronic 
constriction injury of the infraorbital nerve (CCI-ION) (Donegan et al 2013; 
Kernisant et al 2008; Vos et al 1994). This model induces mechanical allodynia 
on the whisker pad of rats because chromic gut suture is used to loosely ligate 
the infraorbital nerve (ION) as shown in Figure 1.6A (Kernisant et al 2008), a 
nerve diverging off the maxillary branch. Although, this has been the most 
popular trigeminal neuropathic pain injury model due to the robust induction of 
chronic hypersensitivity, this model does have its weaknesses. First of all, this 
injury does not induce hypersensitivity in all animals due to the difficulty of tying 
the nerve. The discrepancy comes with the tightness of the ligation. For the rats 
that do develop hypersensitivity, they do not develop allodynia until two to four 
weeks post injury (Bennett & Xie 1988; Ma et al 2012b; Vos et al 1994). The first 
two weeks the injured ION is silent, and it is the demyelination and other 
peripheral and central neuroplastic and glial mediated events that cause the 
hypersensitivity (Evans et al 2014; Taylor 2001; Uchida et al 2010a; Uchida et al 
2010b). Furthermore, this procedure can only be performed in rats. Although, the 
pCCI-ION model was adapted from the CCI-ION to be a specific surgery to be 
performed in mice, this model punctures the ION and is difficult to repeat 
because often times the partial ligation will cause a complete tear of the ION (Xu 
et al 2008).  
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 Our group, however, developed a new chronic trigeminal neuropathic pain 
model for mice known as the Trigeminal Inflammatory Compression (TIC) injury. 
The model is reliable, robust, and reproducible. Instead of ligating the nerve, as 
in the CCI-ION, a small piece of chromic gut suture is placed in the fissure 
between the maxillary bone and the infraorbital nerve. Figure 1.6B illustrates the 
TIC injury with the chromic gut alongside the infraorbital nerve (Ma et al 2012a). 
Our previous study determined the TIC injury model induces mechanical 
allodynia in the mice within one week, which persisted through at least 10 weeks 
in the initial study. Of the mice that receive this surgery, 100% of them develop 
hypersensitivity. Lastly, we defined this not just as a neuropathic pain model, but 
it also includes an inflammatory component because microglial activation is 
observed in the trigeminal dorsal horn making this a very interesting model for 
future continuing experiments (Ma et al 2012a).  
 
1.6 .  Scope and Hypothesis of the Dissertation   
The study described in this chapter of the dissertation will further 
characterize the mouse TIC injury model as a suitable and effective model for 
chronic, trigeminal neuropathic pain studies, and demonstrate its suitability for 
evaluation of drugs that are efficacious in alleviating the mechanical allodynia in 
the mice with TIC injury. 
Behavioral characteristics of mice with the TIC injury were observed at 
time points 1, 4, and 8 weeks post injury using cognitive dependent tests ((light-
dark preference, open field, and elevated plus maze). Mice with TIC injury were 
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then given either FDA approved drugs (Pioglitazone and D-cycloserine) in 
combination and/or separate to observe their inhibitory effects on orofacial 
neuropathic pain.  Finally, assays were performed in isolated mitochondrial 
preparations from the mice with TIC injury for comparisons to mitochondria from 
naïve mice (treated vs. untreated) to determine the mitochondrial bioenergetics 
of each group.   
The hypotheses for this study are that:  
1) Orofacial neuropathic pain after TIC injury would be 
accompanied by anxiety- and depression-like behaviors.  
2) The activation of peroxisome proliferator-activated receptor 
gamma (PPARγ) receptor would elicit anti-allodynic effects in the 
mice with TIC injury. This was tested using the PPARγ agonist, 
pioglitazone (PIO). The prediction is that: A. pioglitazone would 
attenuate mechanical allodynia on the whisker pads of the mice 
with TIC injury, B. PPARγ will be upregulated in the TBSNC, and 
C. the combination of PIO and D-cycloserine (DCS), an N-
methyl-D-aspartate (NMDA) receptor agonist/antagonist, will 
provide a potentiated analgesic effect. 
3) Mitochondrial dysfunction occurring in the mice with TIC is 
partially responsible for the maintenance of chronic pain. This will 
be tested using a mitochondrial uncoupler, 2,4-DNP to determine 
its ability to attenuate the mechanical allodynia on the whisker 
pads of the mice with TIC injury. Furthermore, this dysfunction 
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would be corrected with the PIO+DCS combination treatment ex 
vivo utilizing the Seahorse XFe24 Analyzer. 
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Table 1.1. Chronic Pain is More Prevalent Than Other Major Diseases. 
(Table posted by the AAMP). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Condition Number of Sufferers Source 
Chronic Pain 100 million Americans Institute of Medicine of The National 
Academies  
Diabetes 25.8 million Americans 
(diagnosed and estimated 
undiagnosed) 
American Diabetes Association  
Coronary Heart 
Disease 
(heart attack and chest 
pain) 
Stroke 
16.3 million Americans 
 
7.0 million Americans 
American Heart Association  
Cancer 11.9 million Americans American Cancer Society  
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Figure 1.1. Anatomy of Trigeminal Nerve. The trigeminal system is composed 
of three main nerve branches (V1-opthalamic, V2- maxillary, V3- mandibular) (a). 
The facial dermatomes will synapse accordingly on the descending spinal nuclei 
(b). All nerve meet at the trigeminal ganglion and synapse on the Trigeminal 
Brainstem Sensory Nuclear Complex (TBSNC) composed of main sensory 
nucleus, and descending spinal trigeminal nuclei (sp5): sp5 oralis, sp5 
interpolaris, sp5 caudalis (c). (from de Leeuw, 2008, figure 1-1.) 
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Figure 1.2. Trigeminal Brainstem Sensory Nuclear Complex (TBSNC) with 
Specific Nociceptor Fiber Representation. The majority of primary neurons 
that synapse at trigeminal sp5 caudalis are C -fibers along with a few Aδ delta 
fibers while the primary neurons that synapse at the main sensory nucleus, sp5 
oralis, and sp5 interpolaris are primarily Aβ fibers. (from DaSilva and Dos Santos 
2012, figure 1).  
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Figure 1.3. Functional Magnetic Resonance Imaging (fMRI) of Patient 
Suffering from Trigeminal Neuropathic Pain. Activation areas (red) are 
highlighted along the trigeminal pain pathway after a patient suffering with 
orofacial pain receives a specific stimulus. The image shows that the 
trigeminal ganglia (TG), trigeminal dorsal horn (spV), thalamus (Th), and 
somatosensory (SI) cortex are activated after brush, cold, and heat stimuli 
are applied to the face of patient suffering with orofacial pain. (from 
Becerra, Morris et al. 2006, figure 2)  
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Figure 1.4. The Matrix of “Pain Sensation” and “Pain Affect.” The pain matrix 
incorporates multiple brain regions integrating pain sensation and affect. The 
areas shown are somatosensory cortex 1 and 2 (S1 and S2), posterior parietal 
cortex (PPC), insula cortex, supplementary motor area (SMA), cingulate cortex 
(ACC), prefrontal cortex (PFC), amygdala, thalamus, and periaqueductal gray 
(PAG). (from May, 2009, figure 1). 
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Figure 1.5. The Trigeminal Sensory System in Rodents. (A) The rodent 
trigeminal nerve separates into three branches similar to the human trigeminal 
nerve (from Leiser and Moxon 2006, figure 1). (B) The barrel structure of whisker 
pads of the rodents correspond to the barrel structures observed in the 
brainstem, thalamus and cortex (from Mosconi, Woolsey et al. 2010, figure 1).  
  
A 
B 
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Figure 1.6. The CCI-ION Injury Model in Rats Compared to the TIC Injury 
Model in Mice. (A) The CCI-ION model requires a loose ligation of the ION by 
chromic gut suture that will induce hypersensitivity on the whisker pads of the 
rats 2-4 weeks after surgery. (B) The TIC injury model places the chromic gut 
suture alongside the ION to induce hypersensitivity on the whisker pads of the 
mice within 1 week post-surgery. The arrows point to the ION and the chromic 
gut suture. (figure A is from Kernisant, Gear et al. 2008, figure 1; figure B is from 
Ma, Zhang et al. 2012, figure 1). 
A 
B 
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CHAPTER TWO 
 INDUCED FACIAL PAIN, ANXIETY- AND DEPRESSION RELATED 
BEHAVIORS ASSOCIATED WITH TRIGEMINAL INFLAMMATORY 
COMPRESSION (TIC) INJURY 
 
2.1. Introduction 
Approximately 22% of the US population suffers from facial and 
headache pain. Patients with trigeminal neuropathic pain, one type of chronic 
facial pain, frequently report continuous aching and burning pain sensation that 
may be accompanied by intermittent electrical shock-like experiences. Patients 
who have this type of facial pain also suffer from mechanical allodynia and cold 
hypersensitivity (Baron et al 2010; Zakrzewska 2013). While dental procedures 
or trauma are known causes of peripheral trigeminal nerve injury and 
inflammation, in some cases, no clear causes are identified for the origin and 
maintenance of trigeminal neuropathic pain (Porto F 2011; Renton T 2011).  
There are, however, a limited number of models of such pain conditions 
available for use in laboratory experiments. Historically, one model of 
neuropathic, facial pain frequently used in rats is known as the chronic 
constriction injury of the infraorbital nerve (CCI-ION) (Vos et al 1994). This model 
has been adapted for use in mice and is referred to as the partial CCI-ION (Xu et 
al 2008). These models involve tying chromic gut suture around the ION, a 
branch of the maxillary nerve which innervates the whisker pad of rats and mice, 
causing mechanical hypersensitivity in the whisker pad region. However, the 
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suture causes deformation of the ION and constricts blood flow thus inducing 
partial nerve ischemia and death (Bennett & Xie 1988; Kawamura 1997; Kim 
1992), features not necessarily observed in patients suffering from trigeminal 
neuropathic pain. To address these issues, a novel chronic facial neuropathic 
pain model in mice, named as the Trigeminal Inflammatory Compression (TIC) 
injury model, was developed in our laboratory to more closely mimic the clinical 
characteristics of trigeminal neuropathic pain (Ma et al 2012a). As previously 
reported, the TIC injury model is produced by inserting chromic gut suture 
between the infraorbital nerve and the maxillary bone. This placement alongside 
the nerve, rather than constriction of the nerve, has been successful in 
preventing whole nerve ischemia, demyelination, and death in the small mice 
(Ma et al 2012a). 
Due to its novelty, there is a great need for the TIC injury model to be 
further evaluated to increase our understanding of the behavioral characteristics 
of the model. For example, one important aspect of the clinical presentation of 
trigeminal neuropathic pain not yet evaluated is the common comorbidity of 
psychological disorders and the emotional distress (Wall & Melzack 1999).  In 
clinical populations, symptoms of anxiety and depression in particular have been 
consistently observed in patients with chronic trigeminal-mediated pain (Averill et 
al 1996; Burris et al 2010; Fishbain 1999a; b; M. J. Robinson 2009; McWilliams 
et al 2003; Nicholson & Verma 2004). 
The measurement of constructs such as anxiety and depression in animal 
models, however, has proven more difficult than making these measurements in 
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clinical populations. Fortunately, the use of cognitive dependent tests offers a 
more thorough examination of psychological constructs such a depression and 
anxiety, and are increasingly used by researchers seeking to understand chronic 
neuropathic pain conditions (Mao et al 2008; Mogil 2009). Anxiety-like behaviors 
in animals have been extensively studied, and numerous ones resulted in 
validate protocols (Belzung & Griebel 2001).  Three assays that are particularly 
well understood in measuring animal behavior associated with psychological 
constructs are: the light-dark box preference test, the open field exploratory test, 
and the elevated plus maze task. Furthermore, the activity and rearing behavior 
in each of these tasks has been previously shown to be affected by the 
experience of pain (Bouwknecht & Paylor 2002; Crawley 1980; Parent et al 2012; 
Roeska et al 2008). 
The aim of the current study was to further characterize the novel TIC 
injury model by examining mechanical allodynia and thermal hypersensitivity and 
by measuring pain-related anxiety- and depressive-like behavior with cognitive 
dependent tests. My hypothesis was that mice with TIC injury would display 
greater mechanical allodynia, cold hypersensitivity, and more anxiety- and 
depressive-like behaviors than that of naïve mice or animals undergoing sham 
surgical procedures only.  
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2.2. Materials and Methods 
 
2.2.1. Animals 
 All experiments were performed with C57Bl/6 male, wild-type mice that 
weighed between 25 and 35 grams purchased from Harlan Laboratories 
(Indianapolis, IN). Animals were randomly assigned to receive either 
experimental (TIC injury model) surgical procedures, sham surgical procedures, 
or to remain in the naïve cohort. Mice were housed in a well-ventilated mouse 
housing room (maintained at 27oC) with a reversed 10/14 h dark/light cycle so 
that testing could be performed in their active period. All mice had access to food 
and water ad libitum throughout the duration of the experiment. Low soy bean 
content diet normal chow was provided (Teklab 8626, Harlan, Indiana). All 
experimental procedures were completed according to the guidelines provided by 
the National Institute of Health (NIH) regarding the care and use of animals for 
experimental procedures. Animal protocols were approved by the University of 
Kentucky’s Institutional Animal Care and Use Committee (IACUC). All animals 
were housed in facilities approved by the Association for Assessment and 
Accreditation of Laboratory Animal Care International (AAALAC) and the United 
States Department of Agriculture (USDA).  
 
2.2.2.  Trigeminal Inflammatory Compression (TIC) Injury Surgery 
 Mice were anesthetized with sodium pentobarbital (70 mg/kg, i.p.). Under 
the standard sterilized condition, the hair on the top of their head was then 
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shaved, and ophthalmic cream was applied over their eyes to protect the eye 
from over-dry. Mice were then fully constrained in a stereotaxic frame. A small 15 
mm incision was made along the midline of the head and the orbicularis occuli 
muscle was gently dissected and retracted away from the bone. Small cotton 
balls were packed into the orbital cavity to control bleeding, and the infraorbital 
nerve was located approximately 5 mm deep against the bony fissure. Animals 
randomly assigned to receive the TIC injury surgery underwent surgical 
placement of a 2 mm length of chromic gut suture (6-0), inserted between the 
infraorbital nerve and the maxillary bone infraorbital fissure. Chromic gut suture 
was inserted specifically in this region to adhere to specific infraorbital nerve 
bundles in order to prevent the chromic gut suture from being lost in the orbital 
cavity, but not to pierce the entire infraorbital nerve. Mechanical allodynia was 
induced in the mouse whisker pad due to the suture physically stimulating the 
nerve as well as the chromate salt released from the suture. Animals assigned to 
receive sham surgical procedures did not have the chromic gut suture 
placement, but only received the skin incision and muscle dissection. Naive 
animals did not receive any surgery. All mice were aged matched.  
 
2.2.3.  Behavioral Tests  
 All behavioral tests were conducted during the animal’s active cycle (i.e. 
dark phase of the dark/light cycle) during the hours of 8:00 am to 6:00 pm. During 
testing, either a red-light or a dim lamp was illuminated to allow light for the 
experimenters. None of the behavioral tests were conducted on the same day.  
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2.2.3.1. Assessment of Mechanical Allodynia  
Mechanical threshold of the whisker pad was measured before and after 
surgery with a modified up/down method (Chaplan et al 1994) using a graded 
series of von Frey fiber filaments (force:0.008 g (size:1.65); 0.02 g (2.36); 0.07 g 
(2.83); 0.16 g (3.22); 0.4 g (3.61); 1.0 g (4.08); 2.0 g (4.31); 6.0 g (4.74); 
Stoelting, Wood Dale, IL).  One experimenter gently restrained the mouse in their 
palm (2-5 minutes) with a cotton glove until the mouse was acclimated and calm. 
A second experimenter applied the von Frey filaments to the mouse’s whisker 
pad. The 0.16 g (3.22) fiber was applied first. If the mouse responded three or 
more times out of five trials to the fiber, this was considered to be a positive 
response and the next lower gram force filament was applied. However, if the 
mouse responded two or fewer times out of five to the fiber applied, this was 
recorded as a negative response and then the filament with the next higher gram 
force was applied. Head withdrawal/front paw sweeping/biting all were 
considered positive responses. Time between applications of each filament was 
2-10 seconds. After one fiber successfully caused positive responses, application 
of the subsequent fibers continued until four fibers were applied or until the 
animal responded to the lowest gram force fiber. Data were analyzed with a 
curve-fitting algorithm that allowed for estimation of the 50% mechanical 
withdrawal threshold (measured in gram force). The decreased mechanical 
threshold value is an index of mechanical allodynia. Responses to the von Frey 
fibers stimulations were recorded on day 7 post surgery (TIC and sham) and 
continued once a week post-surgery testing both the ipsilateral and contralateral 
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whisker pads. A cohort of naïve mice were tested intermittently (weeks 2, 4, 8, 
10, 11) alongside the sham animals and mice with TIC.  
 
2.2.3.2. Assessment of Thermal Hypersensitivity 
The protocol used to measure thermal hypersensitivity was adapted from 
Neubert and colleagues (2005) (Neubert et al 2005). Neubert and colleagues 
used a metal probe connected to a water bath placed in an operant licking box. 
The present study utilized a looped copper coil probe (0.065” I.D.; 1/8” O.D.; 
0.030” Wall Thickness, Restek Corporation, Bellefonte, PA) with a 5 x 3 x 3 mm 
tip connected to an insulated rubber tubing and attached directly to an Isotemp 
bath circulator (39.5 x 24.5 x 39 cm, Isotemp 3016S; Fisher Scientific). The water 
bath was filled with antifreeze liquid, and digitally set to a specified temperature 
for testing. The temperature of the copper-wire probe was measured with a 
Physiotemp temperature monitor (Thermalert Model TH-8; PHYSITEMP 
INSTRUMENTS INC. Clifton, NJ, USA). The temperatures reported in this study 
were measured from the tip of the copper-wire probe. The 10-11 ᵒC was chosen 
to activate cold nociceptors; likewise 45-46.5 ᵒC was chosen to activate heat 
nociceptors (Neubert et al 2005; Rossi & Neubert 2009). Room temperature (23-
24.3 ᵒC) and body skin temperature (32-32.5ᵒC) were chosen to act as controls 
for this experiment to ensure that the probe was not causing an adverse 
mechanical response to the animals. The mouse skin was shaved on the 
ipsilateral V2 (trigeminal nerve second branch) region just behind the whisker 
pad 24 hours before testing (Cha et al 2012). One experimenter gently restrained 
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the mouse in their palm with a cotton glove until the mouse was acclimated and 
calm (5 minutes). The other experimenter applied the looped copper-wire probe 
to the shaved V2 region (Figure 2.1.A). Head withdrawal latency, the time in 
seconds from which the stimulus was applied to the time the mouse reacted with 
head withdrawal/front paw sweeping/biting, was recorded. Three trials for each 
temperature were conducted with 1 minute intervals between each trial. Only one 
temperature was recorded per testing day and all thermal testing occurred after 
post-operative week 8. 
 
2.2.3.3. Acoustic Startle Disturbance  
The acoustic startle disturbance test is a well-established measure of 
anxiety-like behaviors in response to a stressful stimulus (Blaszczyk et al 2010; 
Blaszczyk et al 2000; Geyer et al 1982). Mice were placed in a vinyl cylinder 
container (radius: 21.5 cm; depth: 29.9 cm) with room for the animal to move. 
Using a modified form of an acoustic startle disturbance, one experimenter 
pressed a © Top Paw Dog Training Clicker (2" Length “blue bone” clicker; Item # 
39330 purchased from ©Pet Smart, Lexington, KY) above the animal irregularly 
for a period of 2 min. The clicker was pressed with force eliciting an average 
frequency of 430.89 Hz (recorded with a KAYPENTAX COMPUTERIZED 
SPEECH LAB, Real-Time Pitch; Model #5121, version 3.4.1) ranging from 70-
110 dB (Decibel Meter App; Version 1.6; Device Type: iPhone4 iOS Version: 
6.1.3). Mice not currently being tested were housed in a separate sound-proof 
room during the acoustic startle test. Immediately after exposure to the mild 
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acoustic startle disturbance, mice were either placed in the dark side of the light-
dark box or in the central area of the elevated plus maze to begin the test 
designated for that day. Only one of the operant tests was conducted per day. 
 
2.2.3.4. Two Compartment Light-Dark Box Preference Test 
The light-dark box preference task has a long history of use in the 
measurement of anxiety-like behavior. In this task, anxiety-like behaviors are 
believed to manifest as a decrease in:  1) total time spent in the light area, 2) 
number of entries into the light area, and 3) number of rearing/exploratory 
behavior (Bouwknecht & Paylor 2002; Crawley 1980; Hascoet 1998). The light-
dark box consisted of two equally-sized chambers (one illuminated and one 
darkened; 11 x 19 x 12 cm/each) connected with a 5 x 5 cm doorway in which 
mice were allowed to freely move between chambers. Immediately after 
exposure to the mild acoustic startle disturbance (described above), mice were 
placed in the dark side of the box facing away from the light chamber. Animals 
remained in the light-dark preference box for a total of 10 minutes. Behaviors 
measured in this test included: (1) time spent in the light area, (2) number of 
transitions into the light and dark chambers, defined as at least partial passage 
between chambers with extension of at least one of the animal’s back leg from 
one chamber to the next; (3) number of rearing events, a measurement for 
exploratory behavior, (4) latency of the first transition into the light chamber, and 
(5) latency of first re-entry (transition) back into the dark chamber. Behaviors 
were measured at post-operative weeks 1, 4, and 8.   
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2.2.3.5. Open Field Exploratory Activities 
Exploratory behaviors were measured using a Flexfield Animal Activity 
System (San Diego Instruments, San Diego, CA). This apparatus consists of 
two Plexiglas chambers (40 x 40 x 36 cm) equipped with Photobeam Activity 
System (PAS) software coupled to a Compaq 486 computer (Hewlette Packard, 
Palo Alto, CA).  Each chamber contained infrared photobeam sensors with 16 
beams on each axis (total of 32 beams) that are arranged 1.25 cm above the 
chamber floor. Obstruction of these photo beams constitutes movements in the 
x- and y- plane. The x- and y- plane were divided into 5 zones to define the 
center and peripheral area. Another set of 16 beams is located 8 cm above the 
chamber floor to record movements along the z-axis measured i.e. rearing 
events and rearing duration (Zhang et al 2004). Data were collected in 5-min 
intervals for a total of 45 minutes to record: (1) number and duration of rearing 
(2) active time vs. rest time, (3) overall distance travelled, (4) total beam breaks, 
and (5) time spent in the central verses peripheral areas of the chamber. The 
sum of time spent in Zone 1-4 equaled the total duration of time spent in the 
periphery. The duration of time in Zone 5 equaled the duration of time spent in 
the center. Behaviors were measured at post-operative weeks 1, 4, and 8.   
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2.2.3.6. Elevated Plus Maze Task 
The elevated plus maze task is a widely used test for measuring fear and 
anxiety-like behavior and has been previously shown to be affected by rodent 
pain models (Belzung & Griebel 2001; Kontinen et al 1999; Parent et al 2012; 
Roeska et al 2008; Walf & Frye 2007). The elevated plus maze (Bioseb, Vitrolles, 
France) consists of four arm cross-shaped device (length: 35 cm, width: 5 
cm/each, height from floor: 51 cm); two arms are enclosed on three sides by 15 
cm high walls and the other two are not. All arms meet in a central area (5 cm x 5 
cm) which allows animals to move freely throughout each zone of the maze. A 
computer equipped with automated program software (BIOEPM 1.1.14; BIOSEB, 
France) and linked with a camera head (DFK22AUC03) recorded each animal’s 
movement throughout the maze. In this test, the open arms represent a 
potentially threatening environment and thus anxiety-like behavior in response to 
this threat is believed to manifest as a decrease in the time spent in and the 
number of entries into the open arms of the maze (Belzung & Griebel 2001).  
Immediately after the acoustic startle disturbance (described above), mice were 
placed in the central area of the maze and allowed to explore the maze for a 
period of 5 minutes. Mouse behaviors were coded and analyzed off line by a 
blinded observer for: (1) time spent in open arms, (2) number of transitions into 
open and closed arms, (3) number of head dips into the open arms, defined as 
the movement of the animals head from the closed arm to the open arm of the 
maze. Behaviors were measured at post-operative weeks 1, 4, and 8.   
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2.2.4. Statistical Analysis 
The GraphPad Prism 6 statistical program was used for all data analysis 
(Graph Pad Software, Inc. La Jolla, CA). Results are shown as the mean ± 
standard error of the mean (S.E.M.). Data were analyzed by a one-way analysis 
of variance (ANOVA) tests followed by Tukey post hoc test and two-way ANOVA 
followed by Fishers post hoc test (where was appropriate). A p<0.05 was 
considered significant for all tests. 
 
2.3. Results 
 
2.3.1. Animals with TIC Injury Displayed Unilateral Whisker Pads Mechanical 
Allodynia  
 All mice (100%) that underwent TIC surgery developed mechanical 
allodynia on of the ipsilateral but not contralateral whisker pad as determined 
with von Frey fibers thus confirming the results of our previously published paper 
for this model (Ma et al 2012a). For all mice with TIC injury, the mean 50% 
mechanical threshold of the ipsilateral side was 0.03 ± 0.28g an indication of 
mechanical allodynia; while the mean 50% mechanical threshold of the 
contralateral side was 3.72 ± 0.12g (n=13) and did not change from baseline 
(Figure 2.1B). The mechanical threshold of the ipsilateral side of the mice with 
TIC injury were significantly different from the sham animals (ipsilateral, 3.36 ± 
0.07g; contralateral, 3.49 ± 0.05g; n=12) and naïve animals (ipsilateral, 3.55 ± 
0.019g; contralateral, 3.50 ± 0.21g, n=5; p<0.0001, two way ANOVA, Fishers 
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post hoc test) within one week post injury as previously reported (Ma et al 
2012a). The chronicity of this model was further shown by decreased mechanical 
threshold in animals with TIC injury that was present post injury only on the 
ipsilateral side (until the animals are euthanized at week 21). 
The previous study published (Ma et al 2012a) mentioned the presence of 
a receptive field for each mouse, but was not discussed in detail. It is important to 
note that all mice with TIC responded to fiber 0.4 g (3.61) regardless of specific 
receptive field stimulation. In order to find the specific receptive fields of an 
injured animal, the von Frey fibers <0.16 g (3.22) were applied to the whisker pad 
sporadically until a withdrawal response occurred. The sham and naïve animals 
did not respond to fiber 0.4 g (3.61). The location of the receptive field for each 
animal was always the same every week and rarely changed once established 
confirming that the location of the chromic gut suture is not only injuring a 
localized area of axonal fibers along the infraorbital nerve, but also that these 
fibers correlate with a specific receptive field on the whisker pad.  
Three different patterns of sensitivity were identified on the receptive fields 
of the whisker pads of the injured mice (Figure 2.1C). Mouse #1 is 
representative of the most typical receptive field observed (50% of the mice with 
TIC injury had this phenotype).  The second most common pattern is represented 
by Mouse #2 (38% of mice with TIC). However, Mouse #3 (11% of mice with TIC) 
represents a uniquely different phenotype than the previous two in that its 
receptive fields are spread sporadically throughout the whisker pad. Interestingly, 
all mice (100%) subjected to TIC surgery showed a sensitive spot at the 6 o’clock 
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position on the whisker pad (Figure 2.1C, indicated by the red x with a circle). 
The different pattern of receptive fields did not change over the course of the 
animal’s life.   
 
2.3.2. TIC Injury Induced Unilateral Cold Allodynia of the V2 Area 
 Withdrawal latencies for all thermal stimuli were recorded (n=8; Figure 
1D). In the 10-11ᵒC temperature stimuli point, the head withdrawal latency of 
animals with TIC injury (5.11 ± 0.62s) was significantly different compared to that 
of sham animals (9.21 ± 0.88s) and naïve animals (9.75 ± 0.71s; p<0.001, one 
way ANOVA, Tukey post hoc test). The head withdrawal latency of animals with 
TIC for 45-46.5 ᵒC temperature point was 10.21± 1.20s which was not significant 
compared to that of sham animals (9.42 ±1.11s) and naïve animals (8.63 ±0.90s; 
p>0.05).  At room temperature stimuli point (23.24.3ᵒC), the head withdrawal 
latency of animals with TIC injury (15.54 ± 1.52s) were similar to that of sham 
animals (79 ± 0.83s) and naïve animals (17.17 ± 1.13s; p>0.05).   At mouse skin 
temperature (32-32.5ᵒC) point, the head withdrawal latency of animals with TIC 
injury was 20.42 ± 2.37s. This was not significantly different from that of the 
sham (17.25 ± 1.87s) and naïve animals (15.92 ± 1.75s; p>0.05; Figure 2.1D). 
The results indicated that animals with TIC injury were sensitive to mild cold 
stimuli, but had normal reactions to heat, room temperature, and skin 
temperature.   
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2.3.3. Animals with TIC Injury Displayed Anxiety- and Depressive-Like Behaviors 
in Two Compartment Light-Dark Preference Testing 
 Immediately after the 2-min acoustic disturbance the mice were put in the 
dark side of the light-dark box facing away from the light box and the 10 min 
experiment began. Total time spent in light and dark sides, light-dark transitions, 
rearing events and latencies of first cross into light and re-entry into dark were 
measured over the 10 min. There were no significant differences in time spent in 
the light or numbers of rearing events in weeks 1 or 4 post injury. There was no 
significant difference between mice with TIC and sham animals when comparing 
latency of the first cross into the light, latency to re-enter dark side, or the number 
of light-dark transitions (Table 2.1). Both mice with TIC and sham animals spent 
almost 50/50 time in the light or dark side of the box at post-operative week 1 
and week 4. Until post injury week 8, mice with TIC injury spent less time in the 
light, 231.60 ± 25.55s, i.e. they hide in the dark chamber (over 70% of testing 
time). In contrast, the sham mice spent as long as 330.39 ± 43.72s (over 50%) in 
the light chamber (TIC vs. sham P<0.05, Two-way ANOVA, Fishers post hoc 
test, Figure 2.2A). Mice with TIC injury also had significantly less rearing events 
(9.77 ± 1.89/10min) at week 8 post injury compared to sham animals at week 8 
post operation (18.82 ±1.95/10min, Figure 2.2B). When the number of rearing 
events were analyzed by the first and second five minute intervals of the light-
dark box preference, mice with TIC injury still showed significantly fewer numbers 
of rearing events compared to sham animals (Table 2.1). The results of the light-
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dark box preference test indicated that mice with TIC injury develop signs 
associated with anxiety- and depressive-like behaviors 8 weeks after injury.  
 
2.3.4. Acoustic Disturbance Affected Mice with TIC in the Elevated Plus Maze 
Task 
 Immediately after the 2 min acoustic disturbance, both mice with TIC injury 
and sham groups were subjected to an acoustic disturbance on post-operative 
weeks 1, 4, and 8. Mice with TIC injury spent a significant time in the open arm 
(78.90 ± 30.45s) compared to that of sham animals (8.89 ± 3.52s, p<0.01, Two-
way ANOVA, Fishers post hoc test) at week 1 post operation (Figure 2.3A).  
Mice with TIC injury also had a greater number of transitions into the open arms 
at week 1 (4.00 ± 0.67/5min) and week 4 (2.09 ± 0.69/5min) compared to sham 
animals (week 1, 1.50 ± 0.42/5min; week 4, 0.25 ± 0.16/5min; p<0.001, Two-way 
ANOVA, Fishers; Figure 2.3B). The number of head dips into the open arm did 
not differ between the mice with TIC injury and the sham animals at weeks 1, 4, 
an 8 post injury (Figure 2.3C). However, in a separate cohort of animals that did 
not receive the acoustic disturbance stimulation before the elevated plus maze 
task, a  significant difference was not observed in time spent in the open arms 
and the number of transitions when comparing mice with TIC injury and sham 
animals (Table 2.2). These results suggest that the mice with TIC injury 
experience an extinction of fear behavior only after an acoustic disturbance at 
week 1 and 4 post injury. 
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2.3.5. Mice with TIC Injury Showed Less Exploratory Activities 
Animals with TIC injury also showed a decrease in rearing duration 
(153.11 ± 18.22s) and number of rearing events (229.89 ± 27.36) at week 8 
compared to the sham animals (rearing duration, 224.75 ± 25.09s; rearing 
events, 337.46 ± 37.67; P<0.05; Figure 2.4A & 4B). Mice with TIC injury had 
decreased active time (2311.50 ± 63.94s) and increased resting time (388.48 ± 
63.94) 8 weeks after injury compared to that of sham animals (active, 2513.30 ± 
43.15s; resting, 186.72 ± 43.15s; Figure 2.4C & 4D). Mice with TIC injury also 
had decreased total distance traveled compared to sham animals (TIC: 1370.20 
± 110.60cm; sham: 1666.00 ± 114.38cm, P<0.05; P<0.01; Two-way ANOVA, 
Fishers post hoc test; Figure2.4E). A significant difference at week 1 or 4 post 
injury was not observed (p’s>0.5). There was also no difference in total beam 
breaks or center vs. peripheral time duration at any time point (Figure 2.4F, 4G, 
& 4H). The open field results parallel the light-dark box data supporting the 
development of depressive-like behaviors in mice with TIC injury at week 8 post 
injury. 
 
2.4. Discussion 
 
2.4.1 TIC Injury Model Mimics Clinical Facial Neuropathic Pain 
In the present study, we determined that the surgery is 100% efficacious 
for inducing hypersensitivity in all of the animals receiving the chromic gut suture 
placement. All mice experienced mechanical allodynia with distinctive receptive 
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fields (sensitivity spots) that did not change over the course of the animal’s life. 
However, the receptive field pattern variations in the TIC model were due to the 
relative position of the chromic gut suture, the maxillary bone, and the infraorbital 
nerve. The development of cold allodynia in the mice with TIC injury, but not heat 
hypersensitivity was another important feature of this model. Clinic patients with 
neuropathic pain experience cold hypersensitivity but not heat sensitivity (Baron 
et al 2010; Zakrzewska 2013). We also initially determined that the chronicity of 
the TIC injury model lasts at least until 21 weeks. These were the first recorded 
data indicating a mouse facial pain persisting with this time course without 
causing ischemia and complete demyelination of the infraorbital nerve (Ma et al 
2012a).     
Many acute and chronic orofacial models have existed that successful 
induce hypersensitivity in the mouse. However, many of the acute models do not 
last longer than a week and fall short of reflecting the full clinical characteristics 
of chronic facial pain (Bornhof et al 2011; Luccarini et al 2006; Quintans et al 
2014). The chronic models of facial pain have also either differed significantly 
from the clinical picture of patients with trigeminal pain or have had low efficacy 
in mice (Saito et al 2008; Siqueira-Lima et al 2014; Xu et al 2008; Zhang et al 
2012b). The TIC injury model is beneficial because it is not only reliable and 
reproducible, but it also closely mimics the clinical presentation of this pain 
condition. Thus, this study provides support improving the validity for using the 
model.  
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The TIC model demonstrated several aspects consistent with chronic 
facial pain in humans. While the mice with TIC had distinct receptive fields to 
elicit a withdrawal reflex response, human patients also have specific receptive 
fields triggering pain. Likewise, the pattern of the receptive fields were not always 
represented the same in all animals, as the pattern of receptive fields from 
person to person may also vary (Simons & Travell 1981; Siqueira et al 2009; 
Travell 1981). However, the receptive fields in the mice with TIC did not vary over 
the course of the mouse’s life providing a reliable sensitivity area for testing 
evoked hypersensitivity over a chronic period of time. Moreover, as the mice with 
TIC suffered from only cold hypersensitivity, patients suffering with trigeminal 
neuropathic pain are not often bothered by heat stimuli, but instead most often 
complain that light touch, wind, or cold air trigger a shooting pain (De Leeuw 
2008; Zakrzewska 2013). 
 
2.4.2. TIC Injury Developed Anxiety- and Depressive -Like Behaviors Similar to 
Patients Suffering with Chronic Facial Pain 
For the light-dark box preference and open field exploratory test, the 
behavior of the sham mice in weeks 1, 4, and 8 post operation remained 
relatively consistent, but was significantly altered in the mice with TIC injury at 
week 8 post injury. In the light-dark box preference test, the mice with TIC injury 
spent significantly less time in the light side of the box and had a fewer number of 
rearing events. Similarly for the open field testing, the mice with TIC showed a 
decrease in number of rearing events, decreased active time with increased 
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resting time, and a decreased total distance traveled only at post injury week 8. 
Although, cognitive dependent behavioral testing beyond week 8 is not reported 
in this paper, these anxiety-and depressive-like behaviors remained consistent 
throughout the remainder of the animals’ lives parallel with the whisker pad 
sensitization that occurs after the TIC injury.  
Previous research has shown that a decreased amount of time spent in 
the light side of the light-dark box is indicative of anxiety-like behavior while 
decreased number of rearing events and transitions into the light side are 
indicative of depressive-like behavior (Costall & Naylor 1997; Cryan & Holmes 
2005; Fedorova et al 2003). Open field has been used to measure the 
exploratory and locomotor activity of animals including number of rearing events, 
active vs. resting time, and center vs. peripheral time. Decreased number of 
rearing events, decreased active time, and decreased occupancy center time is 
considered a reliable index of anxiety-like behavior and a measure of response to 
anxiolytic agents (Costall & Naylor 1997; Katz & Roth 1979; Ramos et al 1997). 
Together, the results of the light-dark box and open field testing have supported 
that the chronicity of the TIC injury producing anxiety- and depressive-like 
behaviors starting at week 8 post injury. Other chronic pain animal models have 
also observed similar depressive-like behavior after migraine-induced pain, 
sciatic nerve injury, etc.(Dellarole et al 2014; Lipton et al 2000; McWilliams et al 
2003; McWilliams et al 2004; Robinson et al 1988). Furthermore, Yalcin and 
colleagues (2011) similarly reported a time course of chronic pain animals 
revealing the development of depressive-like behaviors also occurring 6-8 weeks 
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post injury (Yalcin et al 2011). These data compared to other studies reported 
suggest that it is the chronicity of the TIC injury model that allows the 
development of the “pain affect” to ensue as another facet observed with 
similarity to patients with chronic pain.   
Wall & Melzack (1999) described chronic pain as having two main 
features: “pain sensation” and the “pain affect” which has incorporated the 
emotional distress the patients undergo due to the pain (Wall & Melzack 1999).  
The “pain affect” has also been described as the sequela of other physical and 
psychological disorders such as anxiety and depression (Dellarole et al 2014; 
Maletic & Raison 2009; McWilliams et al 2003; McWilliams et al 2004). These 
comorbidities have been so prevalent that approximately half of all patients 
suffering from chronic pain have also suffered from anxiety and depression 
((Asmundson & Katz 2009; Asmundson & Taylor 2009; Macianskyte et al 2011; 
Robinson et al 2009).  The relationship between chronic pain, depression, 
anxiety, and fear is extremely complex with extensive overlap making it difficult to 
determine a pattern of cause and effect. This complex relationship could be 
related to the numerous brain structures, such as the somatosensory cortex, 
prefrontal cortex, nucleus accumbens, insular cortex, anterior cingulate cortex, 
amygdala, hippocampus, thalamus, and cerebellum involved in pain perception 
have all also been highlighted as major players in affective states, including 
depression, anxiety, and fear (Apkarian 2004; Apkarian et al 2004a; Apkarian et 
al 2004b; Averill et al 1996; Becerra et al 2006; Dellarole et al 2014; Fishbain 
1999a; b; Robinson et al 2009). Thus, the TIC injury model seems to be a 
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representative model of anxiety-related chronic facial pain. This makes it a good 
model for testing pharmaceutical agents with potential for facial pain relief, and 
also for testing anxiolytics agents, such selective serotonin reuptake inhibitors 
(SSRIs), and other antidepressants to attenuate pain as well as comorbid 
psychological effects.  
 
2.4.3. Decreased Fear Response in Mice with TIC after Acoustic Disturbance  
The development of the anxiety- and depressive-like behaviors at week 8 
post injury was interesting considering that the elevated plus maze results 
showed opposite behavior at weeks 1 and 4 post injury. Mice with TIC injury 
spent more time in the open arm at week 1 post injury and had a significantly 
greater number of transitions at weeks 1 and 4 post injury compared with that of 
sham mice. One could argue that these results represented anxiety-like behavior 
in our sham animals (Table 2.2); likewise, the sham animals were not 
significantly different from the naïve animals in time spent in open arm and 
number of transitions. Therefore, the data strongly support the idea that the TIC 
injury was the cause of the behaviors observed. Interestingly, our results in the 
elevated plus maze suggest that after acoustic disturbance, the mice with TIC 
injury were showing evidence for decreased anxiety at week 1 and possibly week 
4 post injury (Bailey & Crawley 2009; Davis et al 1997). Mice with TIC that were 
not exposed to the acoustic disturbance, however, did not show a significant 
difference in time spent in the open arm or number of transitions compared with 
that of sham animals also not exposed. These results raise some interesting 
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questions: 1) Why was there decreased anxiety-like behaviors at week 1 post 
injury and increased anxiety-like behaviors at week 8 post injury in the mice with 
TIC only after an acoustic disturbance? 2) Were the behaviors in the elevated 
plus maze task not anxiety-like behaviors at all? I offer possible reasons for these 
results in the discussion below.  
One explanation is that the mice with TIC were exposed to two additional 
stressful stimuli in an already sensitized state. The first stressful stimulus was the 
mild acoustic startle stimulation. An acoustic startle disturbance has been shown 
to create a “stress-induced analgesia” by inducing endogenous opioids release, 
thereby, creating the possibility that the animal is in a less painful condition (Frew 
& Drummond 2008; Lewis et al 1980; Nencini et al 1984; Terman et al 1984; 
Vitale et al 2005; Watkins & Mayer 1982). The acoustic stimulus has also been 
shown to activate the HPA axis which would not only cause an increase in 
activity, but also would similarly decrease neuropathic pain (Buijs et al 1993; 
Buijs & Van Eden 2000; Gonzales et al 2008; Kosten & Ambrosio 2002). Since 
the separate cohort of animals who did not receive the acoustic disturbance did 
not have the same behavioral results, the acoustic disturbance might have 
induced a temporary “stressed-induced analgesia” as a potential reason for the 
increased time spent in open arms and increased number of transitions.   
Although, the acoustic stimulation did not appear to have much effect on 
the mice behaviors in the light-dark box preference test, it was possibly an 
important stressor in the elevated plus maze test, the second stressful stimulus.  
This test was more stressful than the light-dark box and open field, and the 
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former could have triggered anxiety-like activities that the latter two did not (Cruz 
et al 1994; Rodgers 1997; Rodgers & Dalvi 1997; Salas et al 2003; Walf & Frye 
2007). Thus, this would contribute to the results observed in the elevated plus 
maze at weeks 1 and 4 after injury in the mice with TIC. The increased number of 
transitions into the open arm possibly suggests hyperactivity, and the increased 
time spent in open arm could suggest a temporary decrease in pain sensation.  
Another possible explanation for these data was that there was a 
decrease in fear/defensive behavior due to poor decision making in the injured 
animals after the acoustic startle stimulation in the elevated plus maze task. This 
could be due to lack of fear associated with increased release of endogenous 
opioids or due to major sites in the brain which might be undergoing plasticity at 
different time points following the injury. Neugebauer and colleagues (2004) 
described the amygdala as being a multi-functional integration site (Neugebauer 
et al 2004). The pre-frontal cortex, amygdala, and ventral hippocampus are just a 
few areas of the brain crucial in fear and stress responsive behaviors (Ji et al 
2010; Neugebauer et al 2004; Quirk et al 2000; Rea et al 2013). Rodents that 
have received excitotoxic lesions localized to the pre-frontal cortex, amygdala, 
and ventral hippocampus have also shown a significant more time spent in open 
arms and increased number transition compared with that of sham animals 
(Quinn et al 2002; Shah & Treit 2003; Ventura-Silva et al 2013).  Negative 
emotions such as anxiety and depression facilitated pain, but the negative 
emotions associate with fear and stress promoted the inhibitory pathways of the 
amygdala which then inhibited pain. This interpretation allows for a possible 
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coexistence of depression, fear, and pain. Therefore, if certain pharmaceutical 
agents were devised or used that not only treated depression, but also pain, then 
perhaps our understanding of these mechanisms and treatment would be 
improved. 
 
2.5. Conclusion 
In summary, due to the efficacy and persistence that is translationally 
relevant to the chronicity of the clinical injury, the TIC injury model is a good 
chronic trigeminal pain model that can be used to determine different signaling 
cascades initiated during the course of facial pain. This will help not only to 
identify molecular targets, but also to define differences between facial pains 
versus somatic pain relayed by the spinal cord after nerve injury. Since the TIC 
injury model has been developed in mice, gene therapies can be used in order to 
target particular cytokines, proteins, and receptors in the hopes of revealing 
underlying mechanisms and how specific gene knock-outs influence trigeminal 
pain. Furthermore, since this model displays anxiety- and depressive-like 
behaviors by 8 weeks, it is a useful model to study certain pharmaceutical agents 
that perhaps can help attenuate not only depression/anxiety, but also fear, 
anxiety, and depression related to pain. 
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Table  2.1. Light-Dark Box Data. 
Week Group 
Latency to 
first cross 
(s) 
Light/dark 
Transitions 
(#) 
Latency to 
re-enter 
dark side 
(s) 
Rearing Events 
 
1
st
 2
nd
 
 
0 Naïve 41.53±12.45 9.88±1.37 21.06±8.70 11.88±1.61 6.00±1.12 
 
1 TIC 
 
56.17±12.53 
 
10.38±1.29 
 
21.09±3.77 
 
9.33±0.81 7.57±1.08 
 
1 SHAM 
 
40.55±13.91 
 
11.13±1.29 20.29±5.67 9.88±1.42 8.00±1.00 
 
4 TIC 
 
23.48±9.88 
 
 
9.83±1.90 
 
 
65.66±24.86 
 
10.58±1.54 6.5±1.91 
 
4 SHAM 
 
23.85±10.26 
 
 
11.17±1.36 
 
48.64±35.44 10.42±1.36 6.50±1.12 
 
8 TIC 35.52±11.70 
 
9.38±1.47 
 
 
31.61±16.18 
 
5.46±1.23 4.31±0.77 
 
8 SHAM 
 
13.08±5.47 
 
 
11.55±1.89 
 
 
18.33±3.59 
 
9.73±1.24 9.09±0.97 
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Table  2. 2.  Elevated Plus Maze Data. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Week Group 
Open Arm 
Duration (s) 
Transitions 
into Open 
Arms (#) 
Head Dips into 
Open Arms (#) 
 
0 
 
Naïve 
 
21.43±7.86 
 
2.38±0.75 10.75±0.99 
 
1 
 
TIC 
 
78.90±30.45 
 
 
4.00±0.67 
 
8.36±1.52 
 
1 
 
SHAM 
 
8.89±3.52 
 
 
1.5±0.42 
 
11.38±1.60 
 
4 
 
TIC 
 
17.11±5.58 
 
 
2.09±0.69 
 
 
6.18±1.03 
 
4 
 
SHAM 
 
0.93±0.61 
 
 
0.25±0.16 
 
 
4.13±0.90 
 
4 
 
TIC 
(NS) 
 
8.13±4.66 
 
 
0.63±0.32 
 
6.00±1.82 
 
4 
 
SHAM 
(NS) 
 
0.00±0.00 
 
 
0.00±0.00 
 
 
5.50±0.98 
 
8 
 
TIC 
 
1.44±0.79 
 
0.45±0.21 
 
 
5.64±1.13 
 
8 
 
SHAM 
 
0.00±0.00 
 
 
0.00±0.00 
 
 
5.00±1.05 
 
8 
 
TIC 
(NS) 
 
0.887±0.89 
 
0.13±0.13 
 
 
3.13±0.44 
 
8 
 
SHAM 
(NS) 
 
1.94±1.31 
 
 
0.25±0.16 
 
 
2.38±0.38 
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Figure 2.1. TIC Injury Induced Mechanical and Cold Allodynia. The mice with 
TIC were tested on the whisker pad for mechanical allodynia and thermal 
hypersensitivity in the V2 area behind the whisker pad (A). The ipsilateral 
whisker pad of the mice with TIC had a significant decrease in mechanical 
threshold than that of their contralateral side and the sham and naïve mice 
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starting within the first week post injury lasting until euthanasia, 21weeks post 
injury (B). The patterns variations of the receptive fields are shown in (C) with 
100% of the mice receiving the TIC surgery developing allodynia. Mice with TIC 
are only hypersensitive to cold temperatures (D). n= 7-10; Two way ANOVA, 
Fishers post hoc test ****p<0.0001; One way ANOVA, Tukey post hoc 
***p<0.001.  
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Figure 2.2. Mice with TIC Had Anxiety- and Depressive-Like Behavior in the 
Light-dark Box. Mice with TIC spent significantly less time in the light side of the 
light-dark box at post injury week 8 compared with that of the sham animals (A). 
Mice with TIC showed a decrease number of rearing events at post injury week 8 
as compared to the sham mice (B). Naïve animals behavioral baselines are 
indicated by the dotted line; n= 8-21, Two way ANOVA Fishers post hoc test 
**p<0.01,*p<0.05.  
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Figure 2.3. Acoustic Disturbance Affected Mice with TIC in the Elevated 
Plus Maze. Mice with TIC spent significantly more time in the open arms post 
injury week 1 compared with that of the sham animals (A). Mice with TIC showed 
a significantly more number of transitions into the open arms at post injury week 
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1 and 4 as compared to the sham mice (B). Head dips into the open arms were 
not significantly from mice with TIC compared to that of sham mice (C). Naïve 
animals behavioral baselines are indicated by the dotted line; n= 8-11, Two way 
ANOVA Fishers post hoc test ***p<.001, **p<0.01,*p<0.05. 
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Figure 2.4. Mice with TIC Injury Showed Decreased Exploratory Activity in 
Open Field. Mice with TIC had a significantly fewer rearing events and rearing 
compared to sham mice post injury week 8 (A&B). Mice with TIC had 
significantly less active time and increased resting time post-op week 8 
compared with that of sham mice (C&D). Mice with TIC traveled less overall 
distance post-op week 8 compared with that of sham mice (E). No significant 
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difference was detected in beam breaks (F), central (G) or peripheral (H) time 
duration. N=8-19, Two-way ANOVA, Fishers post hoc test, **p<0.01,*p<0.05. 
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CHAPTER THREE 
RAPID EFFECTS OF PPAR-AGONISTS ON ATTENUATION OF 
TRIGEMINAL PAIN 
 
3.1. Introduction 
Trigeminal neuropathic pain is an orofacial pain condition characterized by 
continuous aching and burning sensation caused by trigeminal nerve 
damage(Zakrzewska 2013). Dental procedures or trauma can cause trigeminal 
peripheral nerve injury and inflammation, but in some cases, the cause is 
unknown. Clinicians most often resolve treating this continuous trigeminal 
neuropathic pain with inadequate anticonvulsants and antidepressant 
((Asmundson & Katz 2009; De Leeuw 2008; Robinson et al 2009; Roditi et al 
2009). Therefore, there is a great need for discovery of new drug targets. 
Peroxisome proliferator-activated receptor (PPAR) is a nuclear receptor 
with three isoforms: alpha, beta/delta and gamma.  PPAR is widely expressed in 
adipose, liver, cardiac, endometrial stromal cells, immune cells, neurons,  and 
glia of the peripheral and central nervous system (Cimini et al 2005a; Cimini et al 
2005b; Cristiano et al 2005; Cullingford et al 2002; Gray et al 2012; Li et al 2010; 
McKinnon et al 2012; Park et al 2007; Sarruf et al 2009). After ligand-activation, 
the PPAR transcription factors of the nuclear hormone receptor superfamily plays 
a major regulatory role in energy homeostasis and metabolic function (Michalik & 
Wahli 2006). These receptors form a heterodimer with retinoid X receptor (RXR) 
controlling gene expression of PPAR response elements (PPRE) on DNA 
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(Berger & Moller 2002; Moore et al 2001; Sanz et al 2012; Szanto et al 2004). In 
particular, the activation of the peroxisome proliferator-activated receptor isoform 
gamma (PPARγ) has shown to have multiple downstream effects. 
PPARγ is activated by endogenous lipids or by thiazolidinediones, such as 
rosiglitazone and pioglitazone (PIO), which is FDA approved for the treatment of 
type 2 diabetes. These agonists have been shown to regulate fatty acid 
metabolism (Nagashima et al 2005; Szanto et al 2004; Willson et al 2001). 
However, more recent studies suggest PPARγ activation plays a role in another 
major pathway that suppresses neuroinflammatory mediators, such as NF-κB 
(nuclear factor kappa-light-chain-enhancer of activated B cells), thereby 
decreasing microglial activation and certain cytokines such as TNF-α (tumor 
necrosis factor alpha) and IL-6 (Interleukin 6) (Berger & Moller 2002; Combs et al 
2000; Maeda & Kishioka 2009; Sadeghian et al 2012). As well as showing a 
reduction in paw edema after capsaicin injection, PPARγ activation also reduces 
mechanical allodynia and thermal hyperalgesia in the sciatic nerve injury animal 
model (Fehrenbacher et al 2009; Ghosh et al 2007; Maeda & Kishioka 2009; 
Morgenweck et al 2010; Morgenweck et al 2013; Park et al 2007). Furthermore, 
PPARγ has been shown to be upregulated in Schwann cells after nerve injury 
(Cao et al 2012; Zhang et al 2010). Other studies have found that the PPARγ 
receptor is upregulated specifically within two weeks after an optic nerve injury in 
a mouse and then decreases down to normal levels for later time points (Zhu et 
al 2013).  
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Although PPARγ activation has been highly implicated in decreasing 
specific types of neuropathic and inflammatory pain, the effects of PPARγ 
activation on trigeminal pain has never been studied. Although, Moreno et al. 
indicated PPAR to be in the trigeminal nucleus (Moreno et al 2004), but no one 
has explored the function of this receptor in the Trigeminal Brainstem Sensory 
Nuclear Complex (TBSNC) which is composed of four nuclei name rostral to 
caudal: main sensory nucleus (principal nucleus 5), spinal trigeminal oralis, 
spinal trigeminal interpolaris, and spinal trigeminal caudalis (De Leeuw 2008; 
Sessle 2000). The TBSNC consists of second order neurons that relay tactile 
and painful stimulation to the thalamus which then transmit  the signals to the 
sensory cortex (layer IV) corresponding to the relevant head/neck/facial region 
making up the trigeminothalamic pathway (DaSilva & DosSantos 2012; De 
Leeuw 2008; Sessle 2000). Therefore, the TBSNC is vital to trigeminal 
nociception transmission. 
The aim of this current study is to determine the role of PPARγ in trigeminal 
neuropathic pain utilizing our novel Trigeminal Inflammatory Compression (TIC) 
injury model in mice (Ma et al 2012a). Our hypotheses are that 1) PPARγ is more 
immunoreactive in the mice with TIC injury and 2) PIO attenuates trigeminal TIC 
injury pain dependent on PPARγ activation. We evaluated: 1) PPARγ 
immonoreactivity in the TBSNC with/without TIC injury, 2) systemic 
administration of PIO, PPARγ agonist, in the mice with TIC injury to assess the 
attenuation of trigeminal pain, and 3) systemic administration of PPARγ 
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antagonists to better determine whether PIO acts through PPARγ dependent 
pathways in the attenuation of pain.  
 
3.2. Materials and Methods 
 
3.2.1. Animals 
See chapter 2; section 2.2.1. 
 
3.2.2. Trigeminal Inflammatory Compression (TIC) Surgery 
See chapter 2; section 2.2.2. 
 
3.2.3. Assessment of Mechanical Allodynia on the Mouse Whisker Pad 
See chapter 2; section 2.2.3.1. 
 
3.2.4. Immunohistological Study 
Mice with TIC, 3 weeks post injury and aged matched naïve mice were 
anesthetized with isoflurane and decapitated. This early time point was based on 
previous literature that indicated PPARγ changes occur at earlier time points 
(Cao et al 2012; Zhu et al 2013). The brainstem was dissected and then placed 
in 4% paraformaldehyde in 0.1 M phosphate buffer solution (PB, pH 7.4) for 42 
hours. This was followed by a 24 hour soak in 30% sucrose in PB. The 
brainstems were then embedded in OCT Compound (Tissue-Tek, Sakura, 
Torrance, CA) and sectioned with a cryostat at the thickness of 40 microns and 
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sequentially placed in 24-well plates filled with Ethylene Glycol based anti-freeze 
solution, stored at -20°C for immunohistological study. To insure the integrity of 
the stain and control for variability, all tissues were simultaneously processed for 
staining on the same day. On the day of immunostaining, the tissues were 
washed with 0.1M PBS (pH 7.4) and pretreatment with 3% hydrogen peroxide in 
0.1M PBS (pH 7.4) for 15 min to destroy endogenous peroxidase activity in 
erythrocytes. Tissues were then blocked using 0.5% Triton X-100 in PBS (15min) 
to permeabilize cell membranes and reduce cell surface tension to increase the 
antibody penetration. The 5% normal goat serum in the PBS (40min) blocked 
nonspecific antigen-antibody combinations. Sections were incubated overnight at 
4°C with rabbit polyclonal anti-PPAR-gamma IgG (1st. antibody) (1:6000 dilutions; 
H-100 Santa Cruz Biotechnology, Dallas, TX). The succeeding day, the sections 
were incubated at room temperature with a secondary bioatinylated goat anti-
rabbit IgG (1:200; company, place) for 40 minutes. The sections were then 
incubated with avidin-biotin complex (ABC) reagent for 40 minutes. Finally the 
antibody-antigen interaction was visualized via a peroxidase-catalyzed reaction. 
After mounting the sections to gel-coated Super Plus glass slides, they were 
allowed to air dry for at least 4 hours before they were dehydrated through 
graded ethanol and xylene. Then the slides were cover-slipped using Permount 
mounting medium (Fishers Scientific, Waltham, MA). The slides were imaged 
using Nikon E1000 microscope (Nikon Instruments, Inc., Melville, NY) equipped 
with a Nikon DXM1200F digital camera and the Act-1 Program. 
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3.2.5. Image Analysis 
The immunostaining intensity of the trigeminal brainstem sensory nuclear 
complex (main sensory, oralis, interpolaris, and caudalis) was analyzed (n=3; 9-
12 tissues/animal) using ImageJ (1.46, NIH). Each subnuclei of the trigeminal 
brainstem sensory nuclear complex was identified as a region of interest and 
analyzed for mean fluorescent intensities. To identify PPARγ immunoreactivity 
differences, each subnucluei of the complex was analyzed separately. The mean 
fluorescent intensities of the trigeminal dorsal horn were measured in mice with 
TIC injury and then compared to that in naïve mice  
 
3.2.6. Drug Preparation and Administration 
  PPARγ agonist, pioglitazone, was dissolved in normal saline followed by 
30 seconds of vortex. Then the solution was sonicated for 20 minutes before use. 
Benzafibrate, PPARα agonist, was dissolved in 1% carboxymethylcellulose and 
was then vortexed for 30 seconds. Fenofibrate, PPARα agonist; GW0742, 
PPARβ/δ agonist and GW9662, PPARγ antagonist were dissolved in 10% 
dimethyl sulfoxide (DMSO) and vortexed for 30 seconds before administration. 
All drugs were fresh prepared on the day just before administration.  
  Drugs were administered after mechanical allodynia was confirmed at 
least 8 weeks post operation to observe the efficiency of each drug in a chronic 
neuropathic pain condition. All doses were chosen based on drug safety, and 
drug efficacy in previous studies   (Fehrenbacher et al 2009; Feinstein et al 2005; 
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Gross et al 1999; Hamano et al 2011; Maeda & Kishioka 2009; Morgenweck et al 
2010; Morgenweck et al 2013; Oliveira et al 2007; Paterniti et al 2012)  
  Given systemically with the following doses: pioglitazone at doses 100 
mg/kg and 300 mg/kg (<10ml/kg volume) was injected intraperitoneal (<10 ml/kg 
volume) and 600 mg/kg was given oral gavage (at the volume of <10 ml/kg). 
Lower doses of pioglitazone (≤100 mg/kg) have been reported in previous 
studies, but when no effect was observed at 100 mg/kg, doses were increased 
accordingly. For a mouse, the reported LD50 of PIO given systemically ranges 
from 181 mg/kg-1200 mg/kg, therefore the 600 mg/kg dose was administered 
orally (United States Pharmacopeial Convention, 2013)]. 
  PPARα agonists, benzofibrate (100 mg/kg p.o.; LD50 500 mg/kg) and 
fenofibrate (200 mg/kg i.p.; LD50 1200 mg/kg), and PPARβ/δ agonist, GW0742 
(1 mg/kg and/or 6 mg/kg i.p.) were given systemically to serve as PPAR 
activation controls. The LD50 of GW0742 has not been reported. 
  In a separate cohort of mice, the PPARγ antagonist, GW9662 (30 mg/kg 
i.p), was injected 30 minutes before the PPARγ agonist, pioglitazone (300 mg/kg 
i.p.) was given. This dose of PIO was chosen because it had the maximum effect 
on the elevation of mechanical threshold in TIC injury animals. GW9662 was 
employed to block PIO from binding to PPARγ to see if the effect of PIO is 
specific via activation of PPARγ (Feinstein et al 2005; Lea et al 2004; Maeda & 
Kishioka 2009). 
  During each drug testing, 50% mechanical threshold was measured at 
time points of 0, 0.5, 1, 2, 3, 4 hours post inject on the ipsilateral whisker pad 
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only. The 600 mg/kg oral dosing of PIO was measured out until 6 hours because 
an attenuated effect was observed starting at the 4th hour post injection time 
point. To increase animal “n” number in the treatment groups for these 
experiments, mice were tested with these drugs using the Latin square type 
crossover method with at least 1 week interval between each drug testing and 
allow sufficient time for the effect of a previous treatment to wear off. Vehicle for 
the PIO study was normal saline. For all other drugs, 10% DMSO was 
administered to the mice with TIC injury to serve as a vehicle. One experimenter 
was blinded to the drugs given to the animals for each experiment. 
 
3.2.7. Statistical Analysis 
  The data were expressed as means  S.E.M. The GraphPad Prism 6 
statistical program was used for data analysis (Graph Pad Software, Inc., La 
Jolla, CA). All behavioral data including drug studies were analyzed using a Two-
Way ANOVA with a Fishers post hoc test; Histological studies were analyzed by 
a Two-Way ANOVA with a Tukey post hoc test; (where is appropriate) p≤0.05 is 
considered significant. 
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3.3. Results 
 
3.3.1 Mice with TIC Injury Demonstrated Unilateral Whisker Pad Mechanical 
Allodynia  
  The 50% baseline mechanical threshold was initially the same on both 
side of the whisker pad of mice with/without TIC (3.51 ± 0.18 g for the left; 3.74 ± 
0.45g for the right). The mice with TIC injury experienced unilateral mechanical 
allodynia on the ipsilateral whisker pad within one week post operation lasting 
until the euthanasia day (week 14 post-injury). The mean 50% mechanical 
threshold of the ipsilateral whisker pad for the mice with TIC injury was 0.24 ± 
0.92 g making it statistically significant compared to that on the contralateral 
whisker pad (3.51 ± 0.18 g; n=8; p<0.0001, two-way ANOVA, Fishers post hoc 
test, Figure 3.1). In contrast, the sham operation control mice did not show any 
changes in the mechanical threshold after the surgery. Compared to sham 
operation control mice, the mean mechanical thresholds of the ipsilateral whisker 
pad of the mice with TIC injury was statistically significant (0.24 ± 0.92g vs. 3.51 
±0.36g; n=8; p<0.0001, two-way ANOVA, Fishers post hoc test). 
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3.3.2. The Effect of PPAR Agonists on Mechanical Allodynia of Mice with TIC 
Injury 
 
3.3.2.1. PPARγ Agonist, Pioglitazone, Attenuated Mechanical 
Allodynia in Mice with TIC Injury 
  At 8 weeks post operation, pioglitazone (300 mg/kg i.p.) effectively 
attenuated mechanical allodynia of the ipsilateral whisker pad, the 50% 
mechanical threshold from 0.24 ± 092 g before drug treatment increased to 1.61 
± 0.54 g at hour 1 peaking at hour 2  (2.72 ± 0.74 g) lasting for 3 hours (2.33 ± 
0.98 g; Figure 3.2A). This was statistically significant from those of the mice with 
TIC injury treated with saline injection (2.72 ± 0.74 g vs 0.10 ± 0.04 g; two-way 
ANOVA, Fishers post hoc test, ****p<0.0001; n=3-7). The p.o. administration of 
pioglitazone (600 mg/kg p.o.) also attenuated mechanical allodynia in the mice 
with TIC injury (5hr: 0.87 ± 0.32 g; 6hr: 0.92 ± 0.45 g; two-way ANOVA, Fishers 
post hoc test, *p<0.05; n=3-7) compared that to the saline treated mice with TIC 
injury (0.03 ± 0.00 g; two-way ANOVA, Fishers post hoc test, *p<0.05; n=3-7)  
which is significantly different at 5 and 6 hours post injection. However, this dose 
was not as effective as the 300 mg/kg i.p. of pioglitazone. The 100 mg/kg i.p. 
dose of pioglitazone did not have any effect on the mice with TIC injury 
compared to that of the saline treated mice (0.56 ± 1.40 g vs 0.10 ± 0.04 g). The 
300 mg/kg dose elicited hypothermic side effects that were most likely an 
indication that the dose was too high. However, the 100 mg/kg and 600 mg/kg 
doses did not elicit any observable overt side effects. These results 
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demonstrated that PPARγ receptor is a key player in alleviating whisker pad 
mechanical allodynia in the mice with TIC injury.   
 
3.3.2.2. PPARβ/δ Agonist Moderately Attenuated Mechanical 
Allodynia in the Mice with TIC Injury 
  Allodynia in the Mice with TIC Injury The administration of GW0742, 
PPARβ/δ agonist (6 mg/kg i.p.), partially attenuated mechanical allodynia in mice 
with TIC injury compared to that of the mice with TIC injury treated with vehicle. 
The effect reached peak at hour 2 post injection (1.59 ± 0.55 g vs. 0.06 ± 0.02 g; 
two-way ANOVA, Fishers post hoc test; ****p<0.0001, n= 4-6; Figure 3.2B). The 
GW0742 administration of (1 mg/kg i.p.) provided no attenuation of mechanical 
allodynia (0.51 ± 1.31 g). These results showed that the activation of PPARβ/δ 
isoform play some role in the control of mechanical allodynia induced by the TIC 
injury. 
 
3.3.2.3. PPARα Agonist Had No Effect on the Mice with TIC Injury  
  Two PPARα agonists were used in this experiment. The first one is 
benzafibrate which is a pan-PPAR agonist with the highest affinity for the alpha 
subunit. Benzafibrate at 100 mg/kg i.p. injection, had no effect on mechanical 
allodynia in mice with TIC injury (treated: 0.55 ± 1.34 g vs. vehicle: 0.71 ± 1.52 g; 
two-way ANOVA, Fishers post hoc test; p>0.05, n= 3-6; Figure 3.2C). The 
second and more specific PPARα agonist, fenofibrate, was administered at 200 
mg/kg i.p., no attenuation effect on mechanical allodynia effect (0.56 ± 1.28 g) 
was observed with this drug at this particular dose. These results demonstrated 
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that activation of PPARα at these doses do not contribute to the attenuation of 
the mechanical allodynia in the mice with TIC injury. 
 
3.3.2.4. PPARγ Antagonist, GW9662, Blocked Analgesic Effects of 
Pioglitazone 
  GW9662, a potent antagonist of PPARγ, at the dose of 30 mg/kg (i.p.) 
successfully blocked the actions of pioglitazone (300 mg/kg i.p.) in alleviating 
mechanical allodynia in the mice with TIC (GW9662+PIO: 0.53 ± 1.29 g vs. PIO 
only: 1.55 ± 1.41 g; two-way ANOVA, Fishers post hoc test, N=4-7; ****p<0.0001, 
Figure 3.2D). These results provide evidence that PIO is acting through a 
PPARγ dependent mechanism to attenuate mechanical allodynia. Due to the fact 
that mechanical allodynia in the mouse whisker pad was attenuated post 3 hours 
after PIO injection, support is given to the theory that PPARγ is working through 
nongenomic mechanisms to attenuate trigeminal pain. 
 
3.3.3. PPARγ Was More Immunoreactive in the TBSNC of Mice with TIC injury 
  The entire trigeminal brainstem sensory nuclear complex (TBSNC) 
(composed of the main sensory trigeminal nucleus, and spinal trigeminal oralis, 
spinal trigeminal interpolaris, and spinal trigeminal caudalis was sectioned and 
stained for PPARγ immunoreactivity. The spinal trigeminal dorsal horn (sp5) 
sections were imaged and analyzed for PPARγ immunoreactivity (mean 
intensities) in mice three weeks after TIC injury and along with naïve controls. 
Although the PPARγ positive neurons were expressed in the TBSNC of both 
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mice with TIC and naïve mice, the PPARγ-like immunoreactivity greatly 
increased in the injured animals. Figure 3.3 depicts the mean intensities of the 
immunoreactivity of PPARγ throughout the trigeminal brainstem complex in the 
mice with TIC injury compared to that of the naïve mice. There was a significantly 
higher optical intensity for PPARγ immunoreactivity in the TBSNC of the mice 
with TIC injury. The main sensory nuclei (85.65 ± 19.37), spinal trigeminal oralis 
(65.43 ± 12.68), and spinal trigeminal caudalis (93.59 ± 27.62) on the ipsilateral 
side of TIC injury was compared to that of the naïve mice (main sensory nucleus: 
67.21 ± 14.01; sp5 oralis: 46.42 ± 18.46; sp5 caudalis: 71.76 ± 17.31; p<0.05; 
two-way ANOVA, Fishers post hoc test, n=3 with 9-12 sections/animal). The 
immunostaining intensity in the spinal trigeminal interpolaris of the mice with TIC 
injury (75.61 ± 17.48) did not show significant difference from those of the naïve 
mice (65.64 ± 15.78). However, PPARγ immunoreactivity in the spinal trigeminal 
caudalis of the mice with TIC injury was greater than that of the rest subnuclei of 
the trigeminal brainstem complex and significantly different from the spinal 
trigeminal oralis (p<0.01) and the spinal trigeminal interpolaris (p<0.05; two-way 
ANOVA, Fishers post hoc, n=3 with 9-12 sections/animal). Furthermore, there 
was a bilateral increase in PPARγ immunoreactivity only in the spinal oralis (TIC 
contralateral: 67.22 ± 10.89). 
  Figure 3.4 shows tissue slices of the entire TBSNC in a naïve mouse 
compared to that of a mouse with TIC injury. Sample tissues representing each 
level of the TBSNC from a mouse with TIC injury are depicted in figure panels B-
D (x20). 
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  Figure 3.5 depicts the ipsilateral sp5 interpolaris in the mice with TIC 
injury compared to that in naïve mice. The white arrows indicate the projection of 
whisker barrels of sp5 that have been shown to correlate to the receptive fields 
on whisker pads of the mice (Zembrzycki et al 2013). As indicated at 20x image, 
this is primarily where positive PPARγ neurons were located indicated by the 
black arrows. There also appears to be glial nuclei stained for PPARγ consistent 
with previous findings (Cao et al 2012; Maeda & Kishioka 2009; Sadeghian et al 
2012). Although PPARγ immunoreactivity also appears in the TBSNC of naïve 
mice, the mean staining intensity was much less compared to that of the mice 
with TIC injury. 
    
3.4. Discussion 
 This study determined that the nuclear receptor, peroxisome proliferator 
receptor-gamma isoform (PPARγ), plays a significant role in trigeminal pain 
transmission. Histology revealed that 3 weeks after the Trigeminal Inflammatory 
Compression (TIC) injury, compared to the other subnuclei of the trigeminal 
brainstem complex, a most intense PPARγ immunoreactivity appeared in the 
spinal trigeminal caudalis where the primary pain fibers actually synapse onto. 
Systemic administration of a PPARγ agonist, pioglitazone (PIO), attenuated the 
mechanical allodynia in the mice with TIC injury at doses of 300 mg/kg i.p. and 
600 mg/kg p.o. However, 100 mg/kg of PIO (i.p.) had no effect on the mice with 
TIC injury. Furthermore, these studies revealed that administering a PPARγ 
antagonist, GW9662 (30 mg/kg i.p.) prior to the optimal dose of PIO (300 mg/kg 
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i.p.) blocked the analgesic effect of PIO indicating that PIO is acting through a 
PPARγ mechanism. Additionally, the PPARα agonists, benzafibrate and 
fenofibrate, had no effect on the allodynic mice. However, the PPARβ/δ agonist, 
GW0742 had a minimal attenuation of allodynia effect to the mice with TIC injury. 
Taken together, these results confirm PPAR’s role in trigeminal pain 
transmission. 
 Based on these findings, PPARγ and PPARβ/δ function to inhibit pain 
transmission once activated. However, PPARα does not appear to be a key 
player in trigeminal neuropathic pain. Some controversial studies show that 
PPARα activation have an inhibitory effect on nociception after nerve injury or 
inflammation (Benani et al 2004; LoVerme et al 2006; Maeda & Kishioka 2009; 
Oliveira et al 2007). No study has ever reported PPARα activation eliciting an 
analgesic effect in trigeminal neuropathic pain. However, in this study, the doses 
of the two PPARα agonists could have been increased to possibly provide an 
analgesic effect. Future studies should be conducted to observe if higher doses 
comparable to pioglitazone will attenuate the mechanical allodynia observed in 
the mice with TIC injury. On the other hand, PPARβ/δ agonists have been 
reported to attenuate inflammatory pain (Gill et al 2013; Hall et al 2008), but little 
about this receptor isoform has been reported. The biological role of PPARβ/δ 
has remained elusive due, in part, to its broad tissue expression and the lack of 
good chemical tools with which to study its physiological function. Future studies 
could be conducted to observe PPARβ/δ immunoreactivity in along the trigeminal 
dorsal horn. 
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 Unlike PPARβ/δ, PPARγ has been identified more thoroughly. Upon 
PPARγ activation, it will inhibit not only inflammation, but also neuropathic pain 
after an injury (Fehrenbacher et al 2009; Ghosh et al 2007; Maeda & Kishioka 
2009; Morgenweck et al 2010; Morgenweck et al 2013; Park et al 2007). 
Furthermore, little is known about PPARγ in the trigeminothalamic pathway. 
Moreno and colleagues (Moreno et al 2004) confirmed PPARγ was present in the 
dorsal horn of the brainstem and spinal cord, and Maedo and colleagues (2005) 
(Maeda et al 2005) confirmed Moreno’s findings by using immunohistochemistry 
to identify PPARγ in the sciatic nerve, dorsal root ganglia, and dorsal horn 
supporting PPAR’s representation along the nociceptive pathway.   
 This study was not only the first to identify PPARγ immunoreactivity 
throughout the trigeminal brainstem sensory nuclear complex with/without 
trigeminal nerve injury, but this study also was the first study to demonstrate that 
PPARγ activation attenuates trigeminal hypersensitivity in the TIC injury model. 
This study revealed that PPARγ immunoreactivity increases three weeks after 
the Trigeminal Inflammatory Compression (TIC) injury consistent with other 
findings in which PPARγ becomes upregulated within weeks after a nerve injury 
(Cao et al 2012; Zhu et al 2013). Additionally, the results of this study support 
previous studies demonstrating PPARγ’s presence in neuronal and glial cells 
(Maeda & Kishioka 2009). Although this study identified PPARγ immunoreactivity 
in putative neurons, future double-labeling experiments in the TBSNC with 
PPARγ, neuronal, and glial markers (neuN, IB-4, OX-42, etc.) would serve as 
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more conclusive evidence of PPARγ’s presence in neurons and/or glial cells, 
supporting its role in neurogenic inflammation.  
 Furthermore, PPARγ activation has been shown to transrepress NF-κB 
thereby downregulating pro-inflammatory cytokines  such as IL-6 and TNF-α 
(Berger & Moller 2002; Combs et al 2000; Maeda & Kishioka 2009; Sadeghian et 
al 2012; Scholz & Woolf 2007). Previous studies have even reported that PPARγ 
deficient mice are more vulnerable to inflammatory diseases (Adachi et al 2006; 
Cuzzocrea et al 2004; Straus & Glass 2007). In our previous study (Ma et al 
2012a), we demonstrated microglial activation at the trigeminal dorsal horn of 
mice with TIC injury. Therefore, one possible reason for the increase in PPARγ 
immunoreactivity at the TBSNC observed in the mice with TIC injury could be the 
inflammatory response occurring in the trigeminal dorsal horn. The upregulation 
of PPARγ at the trigeminal nucleus would be a way to combat the neural immune 
system and downregulate the pro-inflammatory cytokines once PPARγ is 
activated.   
 Interestingly, PPARγ immunoreactivity was most intense in the spinal 
trigeminal caudalis of the mice with TIC injury while barely detectable in naïve 
mice. Since the spinal trigeminal caudalis has been identified as the primary 
nucleus for nociceptive signaling (De Leeuw 2008; Sessle 2000), the 
upregulation might partially explain why the PPARγ receptor agonist, PIO, has 
analgesic effects on mechanical allodynia in mice with TIC injury. With the 
upregulation of PPARγ, a stronger anti-inflammatory cell signaling cascade could 
be initiated once PIO binds to its receptor.  
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 However, there is much debate about the actions of PIO. Some scholars 
believe that PIO activates PPARγ to induce transcription while others believe 
there are PPARγ transcription independent mechanisms that occur to decrease 
allodynia  (Fehrenbacher et al 2009; Feinstein et al 2005; Lea et al 2004; Maeda 
& Kishioka 2009; Thal et al 2011). Still, others suspect and have possibly 
demonstrated that PIO can act on other intracellular receptors such as acting on 
a mitochondrial membrane protein known as mitoNEET (Yonutas & Sullivan 
2013). However, in present study, when PPARγ antagonist, GW9662, blocked 
PIO’s analgesic actions, it was then concluded that PIO attenuates trigeminal 
nociception by acting through PPARγ. More studies need to be conducted to 
elucidate the action of PIO non PPARγ dependent pathways.   
 
3.5. Conclusion  
Overall this novel study determined that PPARγ activation by PIO plays the 
most potent role in attenuating mechanical allodynia in the mice with TIC injury. 
This experiment was the first to map PPARγ in the trigeminal brainstem sensory 
nuclear complex as well as show an increase in PPARγ immunoreactivity after 
three weeks post injury. Taken together, these studies provide a new target, 
PPARγ, for attenuation of trigeminal pain which raises the possibility for 
repurposing the FDA approved diabetic therapeutic drug, PIO, for the treatment 
of patients suffering from orofacial pain.  
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Figure 3.1. Mice with TIC Injury Developed Unilateral Mechanical Allodynia 
on the Ipsilateral Whisker Pad. The 50% mechanical threshold on whisker 
pads of the mice with TIC injury and the sham mice were measured bilaterally for 
detecting mechanical allodynia. The 50% mechanical threshold on the ipsilateral 
whisker pad of mice with TIC injury was dramatically decreased within one week 
of injury lasting until euthanasia, week 14. The mechanical threshold on 
contralateral whisker pad of the mice with TIC injury was unaffected by the 
surgery. The mechanical threshold on the whisker pads of the sham operation 
mice did not change (n=9/group; ****p<0.0001, two-way ANOVA, Fishers post 
hoc test). 
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Figure 3.2. Pioglitazone (PIO) Attenuate Mechanical Allodynia in the Mice 
with TIC Injury. Hypersensitivity was blocked by specific PPARγ antagonism 
with (A) PIO rapidly elevating the 50% mechanical threshold in the mice with TIC 
at higher doses (300 mg/kg and 600 mg/kg), but was ineffective at 100 mg/kg 
(n=3-7). (B) GW0742, PPARβ agonist, attenuated mechanical allodynia in the 
mice with TIC at a dose of 6 mg/kg, but it still not as effective as PIO (n=4-6). (C) 
PPARα agonists, benzafibrate and fenofibrate, were not effective in alleviating 
mechanical allodynia in the mice with TIC (n=3-6). (D) PPARγ antagonist, 
GW9662, blocked the effects of PIO at a dose of 30 mg/kg (n=4-7).  *p<0.05, 
****p<0.0001; two-way ANOVA, Fishers post hoc test. 
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Figure 3.3. PPARγ Immunoreactivity Increased in TBSNC of Mice with TIC 
Injury. The Trigeminal Brainstem Sensory Nuclear Complex (TBSNC) was 
stained for anti-PPARγ antibody in the mice with TIC injury and naïve mice. The 
images show the individual subnuclei of the TBSNC (main sensory/principle five, 
spinal oralis, spinal interpolaris, spinal caudalis) and PPARγ immunoreactivity in 
each nucleus. The mice with TIC injury had an increased PPARγ 
immunoreactivity in the main sensory, spinal oralis and spinal caudalis on the 
ipsilateral side compared to those in the ipsilateral side of the naïve mice (n=3 
with 9-12 sections/animal ;*P<0.05, two-way ANOVA, Fishers post hoc). The 
spinal trigeminal nucleus oralis expressed bilateral immunoreactivity that was 
significant greater than tissue from naïve mice (*P<0.05, two-way ANOVA, 
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Fishers post hoc). PPARγ immunoreactivity on the ipsilateral side of the mice 
with TIC injury also was significantly higher in the spinal caudalis compared to 
that of spinal trigeminal oralis and interpolaris (#p<.05, ##p<0.01, two-way 
ANOVA, Fishers post hoc). 
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Figure 3.4. PPARγ  Immunoreactivity Localized Throughout the Trigeminal 
Brainstem Sensory Nuclear Complex in Mice with TIC Injury. (A) The image 
depicts the TBSNC rostral to caudal in naïve mice compared to mice with TIC. 
The subnuclei are indicated as follows (B) principal 5 (Pr5), (C) spinal 
subnucleus oralis (Or5), (D) spinal subnucleus interpolaris (Inter5), and (E) spinal 
subnucleus caudalis (Caud5). 
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Figure 3.5. PPARγ Immunoreactivity at the Spinal Trigeminal Nucleus 
Interpolaris in Sham Mice vs. Mice with TIC Injury. The upper panel depicts 
the ipsilateral side of the naive mice at 10x (A) and 20x (B). The lower panel 
depicts the ipsilateral side of the mice with TIC at 10x (C) and 20x (D). The black 
arrows indicate the PPARγ positive cells and the white arrows indicate the 
projection of whisker barrels that correspond to the receptive fields on the mouse 
whisker pad where most PPARγ positive cells were found. As shown by the 
pictures, the staining intensity of PPARγ immunoreactivity was more intense in 
the tissue from the TIC injured mice than that of the tissue from the naïve mice. 
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CHAPTER FOUR 
 LOW-DOSE COMBINATION OF PIOGLITAZONE AND D-CYCLOSERINE 
ATTENUATED OROFACIAL PAIN BY IMPROVING MITOCHONDRIAL 
DYSFUNCTION 
  
4.1. Introduction 
Chronic trigeminal neuropathic pain is an orofacial pain condition 
characterized by chronic aching and burning sensation sometimes overlaid with 
sharp, electric-like shooting pain caused by trigeminal nerve damage. This injury 
could be due to the compression of the trigeminal nerve by an arteriole pulsation 
or could also be caused by a peripheral nerve injury initiated by dental trauma or 
unknown cause (Burchiel 1993; Cruccu et al 1990; De Leeuw 2008; Devor et al 
2002a; Devor et al 2002b; Jannetta 1967a; b; Love & Coakham 2001). This type 
of injury and pain is very difficult to treat so new therapeutics are needed that 
target key players in the ensuing cell stress that follows.   
The chemiosmotic theory states that during the oxidation of mitochondrial 
complexes, “free energy” in the form of protons (H+ ions) are released into the 
intermembrane space creating the proton motive force (Sheinin et al 2001). In 
healthy mitochondria, the protons will flow back through complex V (ATP 
synthase) inducing ATP synthesis. However, a disruption to any specific complex 
along the mitochondrial electron transport chain (mETC) will lead to one of the 
following energy-dissipating pathways (EDP): 1) decreased electron transport 
along the mETC, 2) increased proton concentration in the intermembrane space,  
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3) lowered ATP production, or  4) increased reactive oxygen species (Brand & 
Nicholls 2011; Starkov 2008; Starkov et al 2004; Wallace & Starkov 2000). Cell 
stress can often be triggered by mitochondrial dysfunction, referring to  any 
energy dissipating pathway (EDP) decreasing mitochondrial bioenergetics  
(Brand & Nicholls 2011; Starkov 2008).  
Studies have indicated mitochondrial dysfunction is a major player not 
only in cell stress, but also in the etiology of inflammatory and chronic 
neuropathic pain that occurs after peripheral nerve injuries (Bouillot et al 2002; 
Ferrari & Levine 2010; Joseph & Levine 2006; Kim et al 2004; Shin et al 2003; 
Sui et al 2013). Joseph and Levine (2006) showed that after administering 
inhibitors to the specific complexes of the mitochondrial electron transport chain 
(mETC), mechanical allodynia was attenuated in animals with sciatic nerve injury  
(Joseph & Levine 2006).  
Other studies have shown that after spinal cord or brain injury, 
mitochondrial dysfunction and oxidative stress also occur within 24 hours of the 
injury (Sullivan et al 2007; Sullivan et al 2004a; Sullivan et al 2004b). However, 
administration of a mild mitochondrial uncoupler, such as 2, 4-Dinitrophenol (2,4-
DNP), has been shown to protect the cortex from mitochondrial dysfunction and 
reactive oxygen species (ROS) production  in mice after spinal cord injury (Brand 
& Esteves 2005; Mahmud et al 1996; Pandya et al 2007; Patel et al 2009). Mild 
uncouplers, such as 2,4-DNP, decrease the proton concentration gradient in the 
intermembrane space by creating protonophores in the mitochondrial membrane 
to allow H+ ions to freely flow across the mitochondrial membrane into the matrix 
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without crossing through the ATP synthase. In naïve animals, this lowers ATP 
production and alters the mitochondrial oxygen consumption. However, during 
cellular stress, mild mitochondrial uncouplers have been shown to decrease the 
production of mitochondrial ROS and increase bioenergetics (Brand & Esteves 
2005; Jin et al 2004; Rolo & Palmeira 2006; Sullivan et al 2004b). 
Although studies have shown that ROS are produced in the trigeminal 
nucleus after peripheral nerve injury and that ROS play a major role in pain 
transmission (Alp et al 2010; Viggiano et al 2004; Viggiano et al 2005; Viggiano 
et al 2010), whether peripheral trigeminal nerve injury can induce mitochondrial 
dysfunction have never been studied to date. 
Furthermore, FDA approved drug, (R)-(+)-4-Amino-3-isoxazolidinone (D-
cycloserine) (DCS), known under the same Seromycin ® (DCS capsules, USP, 
250 mg) is a broad spectrum antibiotic used alternatively for tuberculosis.  It is a 
derivative of the naturally occurring amino acid serine and acts as a partial 
agonist at the strychnine insensitive glycine recognition site of the NMDA 
receptor complex (Furukawa & Gouaux 2003; Hood et al 1989; Monahan et al 
1989; Sheinin et al 2001). Binding of DCS to the NMDA complex enhances 
glutamate activation and increases calcium influx, thus enhancing excitatory 
neurotransmission (Heresco-Levy & Javitt 1998; Tomek et al 2013). However, 
DCS when administered in higher doses has been shown to act as an NMDA 
antagonist to reduce hypersensitivity in sciatic nerve injury in rats (Millecamps et 
al 2007). Clinical trials showed  that DCS is effective in the extinction of acquired 
fear when used as an adjuvant to exposure therapy for anxiety disorders (e.g. 
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post-traumatic stress disorder, phobias, obsessive-compulsive disorder) (Davis 
et al 2006; Heaton et al 2010; Norberg et al 2008). Only one clinical case study 
to date has ever observed the anti-allodynic effects of DCS for alleviation of 
chronic facial pain (Antal & Paulus 2011). Although DCS seems to be a 
prospective new therapy for the treatment of orofacial pain, it has never before 
been thoroughly tested in animals or a mechanism defined. 
Pioglitazone (PIO), FDA approved, is a prescription drug (Actos) of the 
class thiazolidinedione (TZD) with hypoglycemic (anti-hyperglycemic, anti-
diabetic) action to treat type 2 diabetes. Pioglitazone is a selective agonist of the 
nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ). 
However, studies have shown the PIO reduces hypersensitivity in the sciatic 
nerve injury animal model (Fehrenbacher et al 2009; Ghosh et al 2007; Maeda & 
Kishioka 2009; Morgenweck et al 2010; Morgenweck et al 2013; Park et al 2007). 
Many have theorized that PIO is acting through PPARγ to decrease microglial 
activation and oxidative stress (Collino et al 2006; Combs et al 2000; Sadeghian 
et al 2012; Thal et al 2011). However, more recent data has shown that PIO is 
also acting through a PPARγ independent mechanism on the mitochondria by 
directly activating mitoNEET to decrease mitochondrial oxidative stress 
(Geldenhuys et al 2014; Wiley et al 2007a; Wiley et al 2007b; Yonutas & Sullivan 
2013). Recent studies in our laboratory have shown that PPARγ agonist, 
pioglitazone (PIO), attenuates mechanical allodynia in the whisker pads of mice 
after the Trigeminal Inflammatory Compression (TIC) injury primarily by a PPARγ 
dependent pathway (see chapter 3). However, our data also suggest that since 
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the analgesic effect occurs within 2 hours, a PPARγ nongenomic mechanism is a 
possibility. However, PIO’s actions in isolated mitochondria after a peripheral 
trigeminal nerve injury have never been studied. 
  In this study, a trigeminal inflammatory compression (TIC) mouse model 
was employed to investigate the effect of DCS or PIO, and DCS/PIO combination 
on the relief of neuropathic nociception and anxiety associate with trigeminal 
neuropathic pain. The effect of DCS/PIO combination on isolated brain 
mitochondria after a peripheral trigeminal nerve injury was also explored.      
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4.2. Materials and Methods  
 
4.2.1. Animals 
See Chapter 2; section 2.2.1. 
 
4.2.2. Trigeminal Inflammatory Compression (TIC) Injury  
See Chapter 2; section 2.2.2. 
 
4.2.3. Behavioral Assays 
  
4.2.3.1. Detecting Mechanical Allodynia with von Frey Fiber Test 
See chapter 2; section 2.2.3.1. 
 
The assessment of mechanical allodynia after the drug administration was 
only conducted on the ipsilateral whisker pad 8 weeks after injury. This time point 
after injury was chosen since anxiety-and depression-like behavior develops 6-8 
weeks after injury, as discussed in chapter 2 (Yalcin et al 2011). For one-time 
injections, mechanical threshold was measured at 0, 0.5, 1, 2, 3, and 4 hours 
drug injection, with hours 5, 6, 7, and 8 post injection evaluated if drug effect 
persisted. For daily injections, the mechanical thresholds of the mice whisker 
pads were measured once daily at the same testing time each day. This time 
point was determined by the peak effect time point of the one-time injection, and 
usually was between 2.5 - 3 hours after injection. One experimenter was blinded 
to the drugs given at all times. 
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4.2.3.2. Light-Dark Box Preference Testing  
This test is used to observe anxiety-like behavior in the mice with TIC injury 
(saline vs. drug treated). We have already determined that mice with TIC injury 
developed an anxiety-and depressive-like behavior at the 8th week post injury 
indicated by a prolonged duration of the occupancy in the light side of the box 
(see chapter 2, section 2.2.3.4).   
 
4.2.4. Drug Preparation and Administration  
 
4.2.4.1. Drug Preparation 
 
 D-cycloserine (DCS), NMDA agonist/antagonist, was easily soluble in 
normal saline (0.9% NaCl, 10 mg/ml). Pioglitazone (PIO), PPARγ agonist, was 
dissolved in normal saline and vortexed for 30 sec before 20 minutes in the 
sonicator.  2, 4-Dinitrophenol (2,4-DNP) was dissolved in 10% DMSO solution 
followed by a 30 second vortex. 
 
4.2.4.2. Drug Administration 
For subcutaneous (s.c.) injections drug was administered at a volume of ≤ 
5 ml/kg/site using a sterile syringe with a 25G needle. For intraperitoneal (i.p.) 
injection with 25G needle syringe, at a volume of ≤ 10 ml/kg (Turner et al 2011). 
One experimenter was blinded to the drug treatments given for each experiment 
described.  
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4.2.4.2.1. Experiment 1: Treatment of Mechanical Allodynia with 
NMDA Receptor Agonist/Antagonist, DCS 
The mice with TIC were given subcutaneous (s.c.) injections of the 
following DCS doses in mg/kg (40, 60, 80, 100, 160, and 320 in 150 µl/mouse). 
These doses were chosen based on previous published studies (Davis et al 
2006; Kushner et al 2007; Lanthorn 1994; Millecamps et al 2007). All drugs were 
administered at least 8 weeks after TIC injury since anxiety-like behaviors were 
expected to develop 6- 8 weeks post the TIC injury (see chapter 2). The goal was 
to observe the anti-anxiety effects of the drugs. Mechanical allodynia was 
assessed every hour starting at 0 hour time point, for 4 hours. The vehicle control 
mice with TIC injury received a subcutaneous injection of normal saline 
(150µl/mouse)  
At least 8 weeks after the TIC injury, mice started receiving daily 
subcutaneous injections of a low dose of DCS (40 mg/kg, 60 mg/kg, and 80 
mg/kg). In parallel to the mice with TIC injury, sham mice were also given the 
same injections to observe the DCS effects as control. Mechanical threshold was 
measured daily 2.5-3 hours after injection. On the 7th day, the mice receiving the 
80 mg/kg dose went through the light/dark box preference testing. The control 
mice with TIC injury and sham mice received a daily subcutaneous injection of 
normal saline (150µl).  
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4.2.4.2.2. Experiment 2: One-time Injection of Combination of 
DCS/PIO  
In a separate cohort of animals, at least 8 weeks after TIC injury, mice 
received one of the three injections 1) PIO, 100 mg/kg i.p., 2) DCS, 80 mg/kg 
s.c., or 3) Combination injection: PIO, 100 mg/kg i.p. injection quickly followed by 
DCS, 80 mg/kg s.c. injection. As mentioned in chapter 3, the reported LD50 of 
PIO given systemically in a mouse ranges from 181 mg/kg-1200 mg/kg (United 
States Pharmacopeial Convention, 2013). Although, no carcinogenic effects are 
observed in chronic feedings of 100 mg/kg in a mouse, we did not want to risk 
the integrity of the experiment. Therefore, only chronic doses of DCS were given 
with a bolus of PIO (100 mg/kg) on the 7th day. 
Control mice with TIC received an i.p. injection of normal saline (200 
µl/mouse). Mechanical allodynia was evaluated at 0, 0.5, 1, 2, 3, 4, 5, and 6 hour 
post injection time points. 
 
4.2.4.2.3. Experiment 3: 7-day Treatment of 80 mg/kg Dose of DCS 
Followed by a Bolus of 100 mg/kg Dose of PIO on the 7th Day  
At least 8 weeks after the TIC injury, mice started receiving daily 
subcutaneous injections of 80 mg/kg dose of DCS. On the 7th day, in addition to 
the 80 mg/kg DCS dose, the mice were given a one-time bolus of PIO, 100 
mg/kg (i. p.). In parallel to the mice with TIC injury, sham mice were also given 
the same injections. The vehicle control mice with TIC injury and sham mice 
received a daily subcutaneous injection of normal saline (150 µl). Mechanical 
92 
 
threshold was measured daily at 2.5-3 hours after injection. On the 7th day, the 
mice with TIC injury (saline vs. drug group) were placed in the light/dark box for 
preference testing.  
 
4.2.4.2.4. Experiment 4: Single Dose of Mitochondrial Uncoupler 
2,4-DNP 
At least 8 weeks after TIC injury, the BALB/C mice were given either 5 
mg/kg i.p. dose of 2,4, DNP or an i.p. injection of 10% DMSO (250 µl) as vehicle 
control. Mechanical allodynia was assessed at 0, 0.5, 1, 2, 3, 4, 5, 6, 7, and 8 
hour time point after injection. 
 
4.2.5. Mitochondrial Isolation Assays 
 
Isolated Mitochondrial assays were taken from previously described methods 
(Pandya et al 2013; Pandya et al 2007; Sauerbeck et al 2011a; Sauerbeck et al 
2012; Sauerbeck et al 2011b). 
 
 4.2.5.1. Isolated Mitochondria Preparation 
Twenty-eight weeks post TIC injury; mice were euthanized with CO2 and 
rapidly decapitated. Naïve age matched mice were also euthanized as controls. 
The brainstems and brain were quickly dissected and placed on an ice cold 
dissecting plate where the entire cortex was divided from the rest of the brain. 
Then the entire cortex and whole brainstem were utilized for this experiment in 
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order to obtain enough tissue and mitochondria to perform the Seahorse assay. 
The cortex and brainstem were homogenized in separate vials each containing 2 
ml of 4°C mitochondrial isolation buffer (MIB) containing (215 mM mannitol, 
75mM sucrose, 0.1% BSA, 20mM HEPES, 1mM EGTA, pH adjusted to 7.2 using 
KOH). The EGTA (ethylene glycol tetraacetic acid), a calcium chelator, was 
added to improve the mitochondria isolation (Pandya et al 2013; Patel et al 
2009). Tissue homogenates were centrifuged twice at 1300 x G for 3 minutes at 
4°C.  The resultant supernatant was then removed and centrifuged at 13,000 x G 
for 10 minutes at 4°C. The mitochondrial/synaptosomal pellets were burst in a 
nitrogen bomb chamber (1200 psi for 10 minutes at 4°C). After the nitrogen burst, 
the mitochondrial pellets were placed atop of a discontinuous Ficoll gradient 
(7.5% - 10%) and centrifuged at 100,000 X G for 30 min at 4°C. The 
mitochondrial pellet was then resuspended in EGTA-free MIB at 10,000 x G for 
10 minutes at 4°C. The final pellet was resuspended at a concentration of 10 
mg/ml in EGTA-free MIB and was stored on ice until further use. A BCA protein 
assay kit determined the protein concentrations in a Biotek Synergy HT plate 
reader by measuring absorbance at the optical wave length of 560nm (Winooski, 
Vermont). 
 
 4.2.5.2. Bioscience Seahorse XFe24 Flux Analyzer Assay  
The Seahorse XFe24 Flux Analyzer (Seahorse Bioscience, Massachusetts, 
United States) was used to measure the mitochondrial bioenergetics in isolated 
mitochondria preparation as previously described (Pandya et al 2013; Sauerbeck 
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et al 2011b). The day before the experiment, the stock mitochondrial substrates 
and inhibitors were prepared (500 mM pyruvate, 250 mM malate, 30 mM ADP, 1 
mg/ml oligomycin-A, 1 mM FCCP, 1 mM rotenone, and 1 M succinate with the 
pH adjusted to 7.2). The XF Calibrant solution (1ml) was added to each well of a 
24-well calibration sensor cartridge.  This sensor cartridge was then positioned 
on the 24-well calibration plate and placed in a 37°C incubator overnight, the 
calibration sensor cartridge ports A to D were loaded with the appropriate 
mitochondrial substrates/inhibitors at 10x concentrations at the following day. 
The mitochondrial respiration buffer (MRB) consisted of 215 mM mannitol, 75 
mM sucrose, 0.1% BSA, 20 mM HEPES, 2 mM MgCl, 2.5 mM KH2PO4 adjusted 
to a pH of 7.2. The volume of MRB in the mitochondrial plate was based upon 
the original 500µl MRB volume.  
 The brain mitochondrial samples (10 µg) of both mice with TIC and naïve 
mice were analyzed together on a single plate. After being resuspended in MRB, 
50 µl of the mitochondrial samples were added in each experimental well with 
control wells (totaling 4 wells) only obtaining 50 µl of MRB. The XF24 plate was 
centrifuged at room temperature for 4 minutes at 3,000 rpm. For half of the TIC 
and naïve mitochondrial samples (totaling 10 wells), 475 µl of MRB at 37°C was 
added to each well. For the other half of the TIC and naive mitochondrial 
samples (totaling 10 wells) 475 µl of MRB (37°C) containing 50 nM of DCS and 
50 nM of PIO were added to each making a total volume in each well equal to 
525 µl. The plates were then placed in the Seahorse XFe24 flux analyzer for 
mitochondrial bioenergetics analysis following the calibration. 
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 Sauerback and colleagues (Sauerbeck et al 2011b) provide a detailed 
explanation of the cyclic protocol in which the appropriate substrates/inhibitors 
are added to the wells and the measurement of the oxygen consumption rate is 
recorded for each well. The substrates/inhibitors listed above were added from 
port A to port D. Pandya and colleagues (2014) describes the State III response 
after 5mM pyruvate, 2.5 mM malate, and 1 mM ADP were measured (Port A). 
State III is a good indicator of how healthy the mitochondria providing a complex I 
driven ADP phosphorylation rate and ATP synthesis. State IV response is in the 
presence of all the State III substrates/inhibitors including the addition of 1 µM 
oligomycin A (Port B). With the oligomycin A addition, State IV is inhibiting the 
complex V (ATP synthase) action. The Seahorse analyzer will collect data and 
report as percent Oxygen Consumption Ratio (OCR) at each State.  Therefore, 
State III/State IV is known as the Respiratory Control Ratio (RCR) which is used 
to determine how well coupled electron transport is to the production of ATP. A 
RCR that is greater than 5 is reported for healthy mitochondria. 
 
4.2.6. Statistical Analysis 
GraphPad Prism 6 software package (GraphPad Software, Inc. La Jolla, CA) was 
used for graphing and statistical analysis of data from all behavioral tests, drug 
administrations, and mitochondrial assays. Data is shown as mean ± standard 
error of the mean (S.E.M.). Data was analyzed by  two-way analysis of variance 
(ANOVA) followed by Bonferroni post hoc test, or one-way ANOVA followed by a 
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Fishers post hoc test, or by standard, two-tailed, unpaired t-test (where is 
appropriate). A p≤0.05 was considered a significant for all tests.  
 
4.3. Results 
 
4.3.1. Unilateral Facial Mechanical Allodynia in Mice with TIC Injury 
Baseline 50% mechanical thresholds were taken before surgery and were 
similar for mice with TIC injury and sham (TIC: 3.84 ± 0.35 g vs. sham: 3.47 ± 
0.00 g). However, one week post TIC injury the 50% mechanical threshold on the 
ipsilateral whisker pad of the mice decreased to 0.37 ± 0.39 g and this was 
significantly different from that on the contralateral side whisker pad (3.45 ± 0.04 
g vs. 0.37±0.39 g; p<0.0001, two-way ANOVA, Bonferroni post hoc test; Figure 
4.1). The unilateral lowered mechanical threshold started within the first week, 
reached the maximum mechanical allodynia (threshold at the 0 g) at week 1 and 
lasted until the animals were euthanized. The sham mice did not display any 
differences in the mechanical threshold of the whisker pad before and post-
surgery. The 50% mechanical threshold of the ipsilateral whisker pad of sham 
mice was 3.41 ± 0.02 g and contralateral whisker pad was 3.43 ± 0.05 g. 
Comparing the mechanical threshold of the ipsilateral side whisker pad between 
the mice with/without TIC injury, there is also a significant difference (p<0.0001, 
two-way ANOVA, Bonferroni post hoc test; n=9). 
 
97 
 
4.3.2. D-cycloserine Attenuated Mechanical Allodynia But Did Not Relieve 
Anxiety Behaviors Associated with Hypersensitivity  
 Single doses of DCS (40 mg/kg, 60 mg/kg, 80 mg/kg, 100 mg/kg, 160 
mg/kg, and 320 mg/kg) were given in ascending sequence with a one week 
interval between each treatment, given to the mice with TIC injury to determine a 
DCS dose response curve (Figure 4.2A). Only the higher DCS doses, 160 mg/kg 
and 320 mg/kg, were effective in alleviating mechanical allodynia on the whisker 
pad of the mice with TIC injury. At 3 - 4 hour post injection, the mechanical 
threshold of the 160 mg/kg dose treatment group was elevated (hr 3: 0.51± 0.13 
g; hr 4: 0.43 ± 0.12 g) and was statistically significant different from that of saline 
treatment group. (hr 3: 0.00 ± 0.00 g; hr 4:0.01 ± 0.00 g; p<0.0001, two-way 
ANOVA, Bonferroni post hoc test). The mechanical threshold of the 320 mg/kg 
dose group was elevated at 3 hour post injection (0.17 ± 0.11 g) and was 
statistically significant different from that of the saline control mice group (0.00 ± 
0.00; p<0.0001, two-way ANOVA, Bonferroni post hoc test; n=4-8).  
 As shown in Figure 4.2B, the daily dose of 80 mg/kg attenuated the 
mechanical allodynia in ipsilateral whisker pad of the mice with TIC injury on the 
6th day of injection (1.10 ± 0.62 g; n=4-7). Interestingly, the 40 mg/kg and 60 
mg/kg dose of DCS had no effect on the mice with TIC injury, but the sham mice 
that received the 40 mg/kg dose of DCS became hypersensitive to the von Frey 
fiber stimuli on the whisker pad bilaterally (0.37 ± 0.36 g; indicated by the orange 
line in Figure 4.2B). The decreased 50% mechanical threshold was significantly 
different from that of the shams that received the 60 mg/kg dose (3.76 ± 0.23 g) 
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and the 80 mg/kg dose treatment (3.43 ± 0.05 g; p<0.001; two-way ANOVA, 
Bonferroni post hoc test; n=4 - 7). 
 Previous studies have reported DCS is involved in alleviating anxiety-
related disorders (Antal & Paulus 2011; Davis et al 2006; Norberg et al 2008). 
The light-dark box preference test was used to determine if the 7-day treatment 
of DCS would attenuate the anxiety-like behaviors that developed in the mice 
with TIC injury. Figure 4.2C depicts the time of light side occupancy of the mice 
with TIC injury injected with saline (235.30 ± 55.80 sec) vs. the mice with TIC + 
DCS (271.30 ± 65.16 sec; p=0.69; unpaired t test; n=5). Although there is no 
statistical significant difference in the DCS treated mice compared to the saline 
treated, the DCS treated mice did spend substantially more time in the light side.  
This indicated that DCS had minimal effect at the dose tested and would be more 
effective in relieving the anxiety-like behaviors in a higher doses range. 
 
4.3.3. Attenuation of Mechanical Alloydnia and Anxiety by Combination of 
Ineffective Low Doses of D-cycloserine and Pioglitazone 
 A single dose of 100 mg/kg of PIO (i.p.) was determined to be ineffective, 
but the 300 mg/kg dose of PIO was effective in alleviating mechanical allodynia 
in mice with TIC injury (see chapter 3). There are no negative interactions 
reported between PIO and DCS in the literature. There is also no mention of the 
effect of the two drug combination on orofacial neuropathic pain as was explored 
with our TIC injury mouse model. Figure 4.3A depicts the one-time drug dose 
combination of 100 mg/kg (i.p.) of PIO and 80 mg/kg (s.c.) of DCS compared to 
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these same doses given alone in the mice with TIC injury. The mechanical 
allodynia was attenuated in the mice with TIC injury treated with the drug 
combination of PIO +DCS (the 50% mechanical threshold was 0.94 ± .0.34 g) 
and was significantly different compared to that in the saline treated animals 
(0.00 ± 0.00 g; at hour 3 post injection p<0.001, two-way ANOVA, Bonferroni 
post hoc; n=5-9; Figure 4.3B). The effect peak at 2 hour and lasted for 4 hours 
post injection. The effect of the drug combination was also significantly different 
from that of a single dose of 100 mg/kg PIO (0.03 ±0.01 g) or a single dose of 80 
mg/kg DCS (0.06 ± 0.02 g). These one-time doses given alone had no effect on 
mechanical allodynia in the mouse with TIC injury.  
 Following the same experimental method as above for 7-day dosing with 
80 mg/kg (s.c.) of DCS, the study was repeated with the addition of a 100 mg/kg 
(i.p.) bolus of PIO given on the 7th day. The drug combination on the 7th day had 
a greater attenuating effect on mechanical allodynia compared to the effect in 
saline treated mice. Two hours following the injection, the mice were placed in 
the light-dark box for the preference test. The mice treated with the drug 
combination (DCS + PIO) spent a significantly increased amount of time in the 
light side compared to saline treated mice (drug: 221.0 ± 52.33 sec vs saline: 
75.28 ± 36.65 sec; p<0.05, unpaired t-test; Figure 4.3C). Taken together, these 
data demonstrated that combination of PIO and DCS at low dose has a 
potentiating effect. Additionally, this drug combination provided a reversal of 
anxiety-like behaviors associated with the TIC injury, suggesting it could be very 
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beneficial in clinic patients who suffer from chronic orofacial pain and anxiety-
associated with pain. 
 
4.3.4 2.4-DNP Attenuated Mechanical Allodynia in Mice with TIC Injury 
 The mitochondrial uncoupler, 2,4-DNP, has been proven to be 
neuroprotective after traumatic brain injury (Pandya, 2007). At week 8 post injury, 
5 mg/kg of 2,4-DNP, single dose injection (i.p.) effectively attenuated mechanical 
allodynia on the whisker pad of the mice with TIC injury (Figure 4.4). The effect 
started from 2 hour post injection (1.03 ± 0.15 g) and lasted for 5 hour (3hr: 1.64 
± 0.21g; 4hr: 1.17 ± 0.09g: 5hr: 0.83 ± 0.07g). This difference was statistically 
significant compared to mice with TIC injury given vehicle (10% DMSO) (0.02 ± 
0.00g; *p<0.05, ****p<0.0001; two-way ANOVA, Bonferroni post hoc test). The 
effectiveness of this drug in increasing mechanical threshold suggests that 
mitochondrial dysfunction could be a key factor in maintaining the chronic 
mechanical allodynia in the mice after TIC injury. Thereby, drugs that uncouple 
the altered mitochondrial function could be beneficial for relieving chronic pain. 
 
4.3.5. Cortex Mitochondria Had a Decreased Respiratory Control Ratio in Mice 
with TIC Indicating Cortical Mitochondrial Dysfunction 
 The mitochondrial isolation assay and Seahorse XFe24 analyzer was used 
to determine the mitochondrial oxygen consumption of isolated cortical 
mitochondria in the mice with TIC injury. The State III OCR of the mitochondria 
from mice with TIC injury (382.40 ± 10.47) significantly increased compared to 
the State III OCR of the mitochondria from naïve animals (253.9 ± 11.99; 
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p<0.001, two-way ANOVA; Figure 4.5A). The oxygen consumption rate (OCR) of 
State IV increases in the mitochondria from mice with TIC injury compared to the 
mitochondria from the naïve controls (TIC: 86.78 ± 1.93 vs. 47.14 ± 8.54; p<.05, 
two-way ANOVA; Figure 4.5B). This data suggest that the cortical mitochondria 
from mice with TIC injury had increased mitochondrial bioenergetics. However, 
the Respiratory Control Ratio (RCR), defined as RCR = State III/State IV, 
significantly decreased in the mitochondria from mice with TIC injury compared to 
the RCR in the mitochondria of naïve controls (TIC: 4.41 ± 0.07 vs. naïve: 6.64 ± 
1.01; p<0.05, two-way ANOVA; Figure 4.5C).  These results indicate 
mitochondrial dysfunction occurs in the mice with TIC injury since the RCR is 
less than 5. 
The DCS/PIO drug combination (added ex vivo to the MRB) did not 
significantly change State III or State IV OCR. However, the drug combination did 
significantly increase the RCR of the cortical mitochondria of mice with TIC 
(cortex: 6.00 ± 0.71) compared to untreated mitochondria of mice with TIC 
(cortex: 4.407 ± 0.07, p<0.5, unpaired t-test; Figure 4.5C). The drug combination 
significantly decreased the RCR of the cortical mitochondria of naïve mice (4.08 
± 0.21) compared to that of untreated cortical mitochondria from naïve controls 
(6.64 ± 1.008; p<0.5, two-way ANOVA; Figure 4.5C).  
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4.3.6. Drug Combination Treatment Increased Respiratory Control Ratio in 
Brainstem Mitochondria of Mice with TIC Injury  
Isolated brainstem mitochondria of the mice with TIC injury were analyzed along 
with the mitochondria from age matched naïve mice. The OCR of State III and 
State IV of the mitochondria from mice with TIC injury (state III: 502.10 ± 48.26; 
state IV: 70.44 ± 9.43) was not significant compared to the mitochondria of 
naïves (state III: 513.90 ±27.81; state IV: 85.87 ± 9.17; Figure 4.6A & 6B). The 
RCR of the mitochondria of the mice with TIC injury (7.43 ±0.34) compared to the 
mitochondria from naïve mice was not significantly different (6.24 ± 0.35; Figure 
4.6C). However, with the two drug combination, the only significant change 
observed was that the mitochondria drug treated mice with TIC injury had an 
increased RCR compared to the mitochondria from the untreated mice with TIC 
injury (treated: 9.00 ± 0.59 vs. untreated: 7.43 ± 0.34, p<0.05, two-way ANOVA, 
Figure 4.6C).   
 
4.4. Discussion 
In this study, it was determined that higher doses of single injections of 
DCS (160 mg/kg and 320 mg/kg) were efficacious in alleviating mechanical 
allodynia on the whisker pad of mice with TIC injury. However, low doses of DCS 
such as 40 mg/kg induced hypersensitivity in the sham operation control animals. 
Chronic treatment with the 80 mg/kg dose of DCS for 7 days partially attenuated 
mechanical allodynia on the whisker pads of the mice with TIC injury on the 6th 
day. This chronic treatment dose, however, did not improve the anxiety-like 
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behavior associated with TIC injury as shown by the light-dark box preference 
test. The combination of the low dose of DCS (80 mg/kg) and PIO (100 mg/kg) 
was shown to significantly increased the 50% mechanical threshold levels of the 
mice with TIC injury compared to that in saline treated mice with TIC injury as 
well as that in the ineffective single dose of 100 mg/kg PIO or 80 mg/kg DCS. 
Furthermore, the 7-day dose regiment of 80 mg/kg dose of DCS was repeated 
with the exception of the additional bolus of 100 mg/kg dose of PIO given on the 
7th day. This was to mimic the DCS (single drug only) 7-day regiment followed by 
the light-dark box preference test. Single dose of drug combination treatment 
improved not only mechanical allodynia, but also the anxiety-like behavior 
associated with the TIC injury. 
In this study, the mild mitochondrial uncoupler, 2,4-DNP, significantly 
elevated the 50% mechanical threshold on the whisker pads of the mice with TIC 
injury. Although this provides evidence that mitochondrial dysfunction occurs in 
the mice with TIC injury, ex vivo studies were conducted in order: 1) to confirm 
the mitochondrial dysfunction after the TIC injury and 2) to determine if the drug 
combination (DCS\PIO) is acting specifically on the mitochondria to attenuate 
mechanical allodynia. The mitochondrial isolation assays determined that State 
III and State IV OCR increased in cortical mitochondrial, but did not change in 
brainstem mitochondria. However, the RCR did in fact decrease in the isolated 
cortical mitochondria. Furthermore, when treated with the drug combination, the 
RCR of the cortex mitochondria in the naïve mice decreased while those of the 
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mice with TIC injury increased not only in the cortex mitochondria but also in the 
brainstem mitochondria.  
Although clinical trials have been conducted with DCS for alleviation of 
chronic back pain, anxiety/stress disorders, and fear related to pain (Davis et al 
2006; Heaton et al 2010; Norberg et al 2008), only one study has been published 
that observes its attenuation of chronic orofacial pain (Antal & Paulus 2011). 
DCS is known to have an affinity for a specific glycine binding site on the NMDA 
receptor. Previous studies that have shown that at lower doses, DCS will act as a 
partial agonist on the NMDA receptor producing hypersensitivity, but higher 
doses, DCS can act as a partial antagonist of NMDA (Kushner et al 2007; 
Lanthorn 1994). Similarly, the present study found that DCS acts as an agonist at 
low doses (40 mg/kg) inducing hypersensitivity in naïve animals and as an 
antagonist at high doses (160, 320 mg/kg) in the mice with TIC injury for  
alleviation of chronic pain. As explanation for the dual effect, Mony and 
colleagues speculated that many ligands in high doses desensitizes the NMDA 
receptor (Mony et al 2009). 
  Although previous studies have determined that PIO, a PPARγ receptor 
agonist, attenuates neuropathic pain and inflammatory nociception due to 
peripheral nerve injury (Fehrenbacher et al 2009; Ghosh et al 2007; Maeda & 
Kishioka 2009; Morgenweck et al 2010; Morgenweck et al 2013; Park et al 2007), 
the present study was the first to use the drug combination of DCS and PIO to 
treat orofacial neuropathic pain and anxiety associated with TIC injury in a mouse 
model.  It was determined that using ineffective low doses of both DCS and PIO, 
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when combined together, attenuated trigeminal neuropathic pain in the mice with 
TIC injury. This potentiated effect also improved the anxiety-like behavior in the 
mice with TIC injury whereas the DCS only treatment did not. This indicated that 
the drug combination is having a potentiated effect most likely in higher order 
brain regions to attenuate not just pain, but anxiety-related to pain (Dellarole et al 
2014; Lipton et al 2000; McWilliams et al 2003; McWilliams et al 2004; Robinson 
et al 1988). Furthermore, the DCS/PIO combination produced no overt side 
effects observable in the mice with TIC injury. Therefore this drug combination 
could be a very beneficial treatment for patients who are suffering from 
depression, anxiety, or other psychological conditions due to their chronic pain 
status.  
Although DCS and PIO could be acting through the NMDA receptor and 
PPARγ separately, another explanation for this potentiated effect is that these 
drugs are acting through alternative receptors altogether. In fact, some studies 
have supported a role for PIO acting through PPARγ independent pathways 
directly on mitoNEET, a mitochondrial protein. mitoNEET is vital for mitochondrial 
respiration and for increasing mitochondrial bioenergetics (Geldenhuys et al 
2014; Wiley et al 2007a; Wiley et al 2007b; Yonutas & Sullivan 2013). 
Furthermore, Korde and Maragos (2012) successfully identified a NMDA-like 
receptor directly on the mitochondrial membrane (Korde & Maragos 2012). This 
evokes the questions: Is the DCS/PIO combination alleviating trigeminal pain by 
correcting mitochondrial dysfunction through these mechanisms? 
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Although mitochondrial dysfunction has been shown to be responsible for 
maintaining chronic pain after neuronal injury (Bouillot et al 2002; Ferrari & 
Levine 2010; Joseph & Levine 2006; Kim et al 2004; Shin et al 2003; Sui et al 
2013), this is the first study to demonstrate that mitochondrial dysfunction occurs 
in a chronic trigeminal neuropathic pain model.  First, this study determined that 
a mild mitochondrial uncoupler, 2,4-DNP, attenuated mechanical allodynia on the 
whisker pad of the mice with TIC injury. This was supportive reasoning that 
mitochondrial dysfunction was occurring in the mice with TIC. However, it did not 
answer the question of whether mitochondrial function could be improved with 
the DCS and PIO drug combination.  
To further investigate the role of mitochondria in neuropathic pain after 
TIC injury, isolated mitochondrial assays were performed at 28 weeks post injury. 
This study observed the mitochondrial respiration rates of States III and IV in 
particular. These data showed that the cortical mitochondrial of the mice with TIC 
injury have increased State III respiration as well as an increased State IV 
respiration, thereby significantly decreasing the RCR compared to naïve mice. 
However, there were no significant changes in the brainstem mitochondria 
compared to naive mice. This data could be interpreted in many ways.  
First, this data could support an adaptive mechanism that is occurring in 
the cortical mitochondrial of the injured animals. Since the mitochondria was 
analyzed 28 weeks post injury, it is sufficient to say that in a chronic state the 
increased State III respiration is needed to provide sufficient ATP production for  
brain function. However, while State III indicates complex I driven ADP 
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phosphorylation and the general mitochondrial oxidation, State IV is a sufficient 
indicator of electron leak (Brand & Nicholls 2011; Chance & Williams 1955a; b). 
Since State III respiration also increased, this could be supportive of increased 
electron leak that then leads to increased ROS production. However, further 
studies need to be conducted to confirm mitochondrial ROS in the mice with TIC 
injury. Since the respiratory control ratio (RCR) (State III/State IV) was less than 
5 in the cortical mitochondrial of the mice with TIC injury, this would support the 
idea that the complexes of electron transport chain are not very well coupled to 
net production of ATP, indicating mitochondrial dysfunction (Brand 1990; Brand 
et al 1978; Brand & Nicholls 2011).  
Furthermore, the drug combination (DCS/PIO) increased RCR in the 
cortical and brainstem mitochondria, but decreased RCR in the cortical 
mitochondria of the naïve mice. The DCS/PIO combination was able to improve 
RCR suggesting that the DCS/PIO combination improves mitochondrial 
dysfunction after injury, but is not beneficial in naïve mice. An underlying detailed 
mechanism for the DCS and PIO combination effect is unknown and needs to be 
investigated in future studies. Future studies could confirm if this drug 
combination is acting through protein-dependent (NMDA-like receptor in 
mitochondria for DCS and mitoNEET for PIO) or protein-independent 
mechanisms to improve mitochondrial bioenergetics. Future studies looking at 
specific complex activity of the mETC, in particular the redox state of complex I 
could be beneficial in uncovering the mechanism. (Starkov 2006).  
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 Additionally, mitochondrial dysfunction was only detected in the cortical 
mitochondria, but not in the brainstem. This could be due to the fact that there is 
a large area of cortex dedicated to the trigeminal somatotopic map, and thus, a 
higher number of mitochondria in the entire cortex affected compared to the 
brainstem. The trigeminal dorsal horn, on the other hand, is a small portion of the 
brainstem. Nevertheless, the drug combination was acting to increase RCR at 
both levels to ADP phosphorylation. This paralleled improvement of both aspects 
of pain demonstrated with the behavioral tests.  
 Lastly, unlike 2,4-DNP which was removed from the market due to 
increased fatality rates, DCS and PIO, given at their low ineffective dose 
combination, did not induce any observed side effects in the mice. The DCS\PIO 
combination could be a great value in the clinic with patients suffering from 
continuous trigeminal neuropathic pain. 
 
4.5.  Conclusion 
 This study demonstrated that the combination of DCS/PIO attenuated 
not only orofacial neuropathic pain, but also the anxiety behaviors associated 
with the TIC injury through receptor independent mechanisms. These 
mechanisms were supported by the DCS/PIO combination improving the cortical 
mitochondrial dysfunction present in the mice with TIC injury.  
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Figure 4.1. TIC Injury Induced Unilateral Whisker Pad Mechanical Allodynia. 
The 50% mechanical threshold (in gram force) was measured bilaterally on the 
whisker pads of the mice with TIC injury and the sham mice. The mechanical 
threshold was decreased on the ipsilateral whisker pad of mice with TIC injury 
within one week post injury. The mechanical threshold of contralateral whisker 
pad was unaffected by surgery. The mechanical threshold of the ipsilateral and 
contralateral whisker pads of the sham mice also did not change. TIC n=9; TIC 
(ipsi) vs. TIC (con.) or naïve ****p<0.0001, two-way ANOVA, Bonferroni post hoc 
test. 
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Figure 4.2. DCS Attenuated Mechanical Allodynia, but Does Not Reverse 
Anxiety-Like Behavior in the Mice with TIC Injury. (A) Dose response curve 
for DCS showed that higher doses of DCS (160 mg/kg and 320 mg/kg) are 
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effective at alleviating the mechanical allodynia on the whisker pad of the mice 
with TIC injury. (n=6) (B) The mice were given a 7-day treatment of lower doses 
of DCS (s.c.). Only the 80 mg/kg dose elevated the mechanical threshold in the 
mice with TIC injury. The 40 mg/kg dose of DCS lowed the mechanical threshold 
on the whisker pad of the sham mice while the 60 mg/kg dose had no effect on 
sham mice or mice with TIC injury (n=8). (C) On day 7, two hours post-injection, 
the mice with TIC injury treated with 80 mg/kg dose of DCS or went through the 
light-dark box preference test. There is no difference in the time of the light side 
occupancy between drug treated and vehicle treated group. *p<0.05, ***o,0.01; 
****p<0.0001; two-way ANOVA, Bonferroni post hoc test. Figure C: Unpaired t-
test, n.s.; n=5. 
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Figure 4.3. The Combination of DCS and PIO Attenuated Mechanical 
Allodynia and Anxiety-Like Behavior in the Mice with TIC Injury. (A) One-
time dose of DCS (80 mg/kg) + PIO (100 mg/kg) provided a potentiated effect in 
elevating mechanical threshold of the whisker pad of the mice with TIC injury 
which was significantly different than that of the single dose of either DCS (80 
mg/kg) only or PIO (100 mg/kg) only (n=6-8). The mechanical threshold of the 
drug combination treatment group was also significantly different from the vehicle 
treated group. (B) After a 7-day dose of DCS (80 mg/kg), a bolus of PIO (100 
mg/kg) was give on the 7th day. The mechanical threshold was dramatically 
increased in the mice with TIC injury. This was significantly different from that of 
the vehicle treated mice with TIC injury. (C) Two hours following injection of the 
PIO bolus on day 7, the drug and the vehicle treated mice with TIC injury went 
through in the light-dark box preference test (n=8/group). The drug treated group 
showed a significant increase in the time spent in the light chamber compared to 
that of the vehicle treated group (*p<0.05, ***p<0.001; ****p<0.0001; two-way 
ANOVA, Bonferroni post hoc test. Figure C: Unpaired t-test, (*p<0.05.; n=5).  
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Figure 4.4. A Mild Mitochondrial Uncoupler Attenuated the Mechanical 
Allodynia in the Mice with TIC Injury. 2,4-DNP (5 mg/kg) significantly 
increased the 50% mechanical threshold of the mice with TIC injury compared to 
that of the vehicle treated mice. This effect started at one hour, peaked at 3 hour 
and lasted for 5 hours post injection. (n=8; (*p<0.05, ****p<0.0001; two-way 
ANOVA, Bonferroni post hoc test.). 
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Figure 4.5. Isolated Cortical Mitochondria from the Mice with TIC Injury 
Showed an Increased State III and State IV OCR, but Decreased RCR which 
is Reversed With the Drug Combination of DCS + PIO. Cortical mitochondria 
isolated from mice with TIC injury had an increased oxygen consumption rate 
(OCR) for State III (A) and increased OCR in State IV respiration (B). This is 
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significantly different compared to those of the cortical mitochondria from naïve 
mice. The respiratory control ratio (RCR = StateIII/StateIV)) decreased in the 
cortical mitochondria of the mice with TIC injury (C). However, the drug 
combination of DCS and PIO decreased the OCR in State IV, therefore 
increased the RCR (n=8/group; *p<0.05, **p<0.01; two-way ANOVA, Bonferroni 
post hoc test; #p<0.05, unpaired t-test). 
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Figure 4.6. The Drug Combination (DCS +PIO) Increased the Brainstem 
Mitochondrial RCR in the Mice With TIC Injury. There are no significant 
differences in the OCR of State III (A) or State IV (B) for the isolated brainstem 
mitochondria from the mice with TIC injury compared to that of the naïve mice. 
The respiratory control ratio (RCR) did not significant change in the isolated 
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brainstem mitochondrial from the mice with TIC injury compared to that of naïve 
mice (C) However, due to the drug combination treatment (50 nM DCS+ 50nM 
PIO, ex vivo) increased the OCR of the brainstem mitochondria of mice with TIC 
injury at the state III as showed in (A). The RCR of the brainstem mitochondria 
from the mice with TIC injury did increase (n=4/group; *p<0.05; two- way 
ANOVA, Bonferroni post hoc test). 
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CHAPTER FIVE 
 OVERALL DISCUSSION AND CONCLUSIONS 
 
The aims of the study were to develop a new orofacial neuropathic pain 
model specifically for mice that provides a suitable model for study of orofacial 
pain. With this model, the studies sought to identify certain molecular targets that 
play a major role in the etiology and maintenance of trigeminal neuropathic pain.  
 
5.1. Trigeminal Inflammatory Compression (TIC) Injury Is a Clinically 
Relevant Orofacial Neuropathic Pain Model 
This series of studies expands our understanding of the novel facial 
mouse pain model known as Trigeminal Inflammatory Compression (TIC) injury.  
This chronic neuropathic pain model was described in our previous study (Ma et 
al 2012a), but the cold, anxiety- and depressive-like behavioral characteristics of 
this injury were not yet completely characterized. The TIC model demonstrated 
several aspects consistent with chronic facial pain in humans. The first study of 
this thesis determined that the surgery is 100% efficacious for producing facial 
hypersensitivity in all of the animals receiving the chromic gut suture. The 
placement of the suture provides mechanical allodynia with distinctive receptive 
fields (on the affected whisker pad). Likewise, the pattern of receptive fields were 
not always the same in all animals (depending on the nerve fascicle contacted by 
the chromic gut suture), as the pattern of receptive fields from person to person 
may also vary (Simons & Travell 1981; Travell 1981). The development of cold 
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allodynia on the whisker pad of the mice with TIC injury, but not heat 
hypersensitivity is consistent with the clinical profile. Clinic patients suffering with 
trigeminal neuropathic pain are not often bothered by heat stimuli, but instead 
most often complain that light touch, and cold stimuli (De Leeuw 2008; 
Zakrzewska 2013). 
Furthermore, the studies determined that the chronicity of the TIC injury 
model persists at least through 21 weeks.  These were the first recorded data 
indicating a mouse facial pain persisting through this long time course without 
causing ischemia and complete demyelination of the infraorbital nerve (Ma et al 
2012a). Accompanying the hypersensitization were the anxiety- and depressive-
like behaviors. These were supported by the performance of the mice in operant 
tests (light-dark box, open field, elevated plus maze). The anxiety-depressive-like 
behavior was worsened by the acoustic disturbance.  
This again fits into the definition of chronic pain described Wall & Melzack 
(1999) with the two main features of  “pain sensation” and “pain affect” which are 
incorporated into the emotional distress suffered by patients with pain (Wall & 
Melzack 1999).  The “pain affect” has also been described as the sequelae of 
other physical and psychological disorders such as anxiety and depression 
(Dellarole et al 2014; Maletic & Raison 2009; McWilliams et al 2004). These 
comorbidities have been so prevalent that approximately half of all patients 
suffering from chronic pain reportedly also suffered from anxiety and depression 
(Asmundson & Taylor 2009; Carleton et al 2009; Macianskyte et al 2011; 
Robinson et al 2009). The relationship between chronic pain, depression, 
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anxiety, and fear is extremely complex with extensive overlap making it difficult to 
determine a pattern of cause and effect.  This complex relationship is related to 
the numerous brain structures, such as the somatosensory cortex, prefrontal 
cortex, nucleus accumbens, insular cortex, anterior cingulate cortex, amygdala, 
hippocampus, thalamus, and cerebellum that have all been highlighted as major 
players involved not only in pain perception but also in affective states, including 
depression, anxiety, and fear (Apkarian 2004; Apkarian et al 2004a; Apkarian et 
al 2004b; Becerra et al 2006; Dellarole et al 2014; Heim et al 2004; Robinson et 
al 2009). Thus, the TIC injury model is indeed a representative model of anxiety-
related chronic facial neuropathic pain. 
 
5.2. PPARγ Is an Important Molecular Target for the Treatment of 
Trigeminal Neuropathic Pain 
 Our experiment determined that the nuclear receptor, peroxisome 
proliferator receptor-gamma isoform (PPARγ), plays a significant role in 
trigeminal pain transmission.  Immunohistological study revealed that 3 weeks 
after the Trigeminal Inflammatory Compression (TIC) injury, a most intense 
PPARγ immunoreactivity appeared in the spinal trigeminal caudalis where the 
primary nociceptive fibers synapse. Systemic administration of a PPARγ agonist, 
pioglitazone (PIO), attenuated the mechanical allodynia in the mice with TIC 
injury at doses of 300 mg/kg i.p. and 600 mg/kg p.o.  However, 100 mg/kg of PIO 
(i.p.) had no effect. Furthermore, these studies revealed that administering a 
PPARγ antagonist, GW9662 (30 mg/kg i.p.) prior to the optimal dose of PIO (300 
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mg/kg i.p.) blocked the analgesic effect of PIO indicating that PIO is acting 
through a PPARγ activation mechanism. Additionally, the PPARα agonists, 
benzafibrate and fenofibrate, had no effect on the allodynic mice. However, the 
PPARβ/δ agonist, GW0742 had a minimum alleviation of allodynia effect to the 
mice with TIC, but it is not as effective as the PPARγ agonists. Taken together, 
these results confirm PPAR’s role in trigeminal pain transmission, particularly 
signaling through the γ isoform. 
Furthermore, the combination of low doses of DCS (80 mg/kg) and PIO 
(100 mg/kg) were shown to significantly elevate the 50% mechanical threshold of 
the mice with TIC injury. The single dose of DCS only at 80 mg/kg or PIO at 100 
mg/kg was shown to be ineffective. In combination, they produced a potentiated 
effect. Treatment with the single dose combination improved not only mechanical 
allodynia, but also the anxiety-like behavior associated with the TIC injury. 
Therefore, the question is: What defines a molecule as a potential target 
for the treatment of inflammation? Several features should be associated with the 
molecular signature of an inflammatory target. First, the cellular or sub-cellular 
expression of the molecule of interest could be changed upon inflammation. 
Second, the activation of this molecule could cause signs of decreased 
inflammation. Third, the functions of the molecule of interest could be regulated 
by other inflammatory mediators. Finally, the inhibition or activation of this 
molecule should downregulate pro-inflammatory mediators that cause 
inflammation. After reviewing the data, this study demonstrated that PPAR-
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gamma meets all the criteria, thereby supporting this receptor as a potential 
therapeutic target to treat trigeminal neuro-inflammatory pain. 
This study is not only the first study to identify PPARγ immunoreactivity 
throughout the trigeminal brainstem sensory nuclear complex with/without 
trigeminal nerve injury, but this study also is the first to demonstrate that PPARγ 
activation attenuates trigeminal neuropathic/inflammatory pain. In conclusion, 
PPARγ is suggested as a potential therapeutic target in the trigeminal pain 
neuraxis. And from this study also arises the possibility of repurposing the FDA 
approved diabetic therapeutic drug, PIO, for the treatment of patients suffering 
from orofacial pain.  
 
5.3. Mitochondrial Dysfunction is One Underlying Mechanism of Trigeminal 
Neuropathic Pain  
 In this study, the mild mitochondrial uncoupler, 2,4-DNP, significantly 
elevated the 50% mechanical threshold on the whisker pads of the mice with TIC 
injury. This provides evidence that mitochondrial dysfunction occurs in the mice 
with TIC injury.  Ex vivo studies were conducted in order to determine: 1) the 
cause of the mitochondrial dysfunction, and 2) whether the drug combination 
(DCS\PIO) is acting on the mitochondria to attenuate mechanical allodynia. The 
mitochondrial isolation assays determined that the OCR of State III and State IV 
increased in cortical mitochondria, but did not change in brainstem mitochondria. 
However, the RCR did in fact decrease in the isolated cortical mitochondria. 
Furthermore, when treated with the DCS/PIO combination ex vivo, on the 
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isolated brain mitochondria preparation, the RCR of the cortex mitochondria in 
the naïve mice decreased while those of the mice with TIC injury increased not 
only in the cortex mitochondria but also in the brainstem mitochondria. Although 
mitochondrial dysfunction has been shown to be responsible for maintaining 
chronic pain after neuronal injury (Bouillot et al 2002; Ferrari & Levine 2010; 
Joseph et al 2004; Joseph & Levine 2006; Kim et al 2004; Park et al 2006; 
Schwartz et al 2009; Shin et al 2003; Sui et al 2013), this is the first study to 
demonstrate that mitochondrial dysfunction occurs in chronic trigeminal 
neuropathic pain. This study determined that a mild mitochondrial uncoupler, 2,4-
DNP, attenuated mechanical allodynia on the whisker pad of the mice with TIC 
injury. The experiment suggests that the DCS/PIO combination could be acting in 
the brain after TIC injury to improve the brain mitochondrial respiration capacity 
and leads to highly efficient functional performance of the brain, thereby, 
controlling pain related behavior and pain related anxiety.  
 
5.4. Limitations and Future Studies 
Several limitations exist for this study. First, all of our animals were male 
C57Bl/6 mice.  C57Bl/6 mice were chosen for their moderate levels of anxiety-
like behavior (Belzung 2001; Belzung & Griebel 2001; Kulesskaya et al 2014; 
Kulesskaya & Voikar 2014).  In order to collect more consistent results, females 
or other strains were not tested in this study. However, future studies should be 
conducted to observe the behaviors of different species. Since facial neuropathic 
pain in humans is diagnosed more often in females,  behavioral studies 
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performed in chapter two need to be repeated in female mice with TIC injury 
(Koopman et al 2009; Macfarlane et al 2002a; b; Macfarlane et al 2001; Rauhala 
et al 2000).  
Secondly, the operant behavioral tests were only conducted weeks 1,4, 
and 8 post injury. This was done to prevent over-testing of the animals since 
many previous studies suggest only testing occasionally (Walf & Frye 2007). 
However, while anxiety- and depressive-like behaviors could have developed at 
time points earlier than week 8 post injury that our experimental design would not 
have detected, Yalcin (2007) reported that anxiety-like behavior starts to develop 
at 6 weeks post injury. Therefore, a new experimental design could utilize 
different time points such as 2, 6, 10 post injury to observe earlier and later time 
points than 8 weeks post injury to help determine which week precisely the 
anxiety-and depressive-like behavior starts to occur.  
Thirdly, although depressive-like behavior was observed in mice with TIC 
injury, we did not conduct any traditional operant depressive tests such as forced 
swimming test, tail suspension test, and sucrose consumption test (Wang et al 
2012; Zhang et al 2012a).  Because we wanted to measure anxiety-like behavior 
along with depressive-like behavior, assays such as the forced swimming and tail 
suspension tests were not used because they subject the animals to an 
extremely life threatening, stressful environment (Borsini & Meli 1988; 
Sakakibara et al 2005).  However, the sucrose consumption test would be an 
ideal operant test to use to measure depression in the mice with TIC injury as 
well as observe their reward-seeking behavior ((Wang et al 2012; Wyvell & 
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Berridge 2000). Since the mice with TIC revealed poor decision making ability in 
the elevated plus maze test after exposure to the acoustic startle stimulus, the 
sucrose test would also serve the purpose of determining the anhedonic behavior 
of mice with TIC injury. Taken together, future studies combined with the data 
collected here could provide better characterization of the cognitive impairment of 
the mice with the TIC injury. 
Another limitation of these studies is that all of the drug tests using PPAR 
agonists/antagonists were one time dose administrations. In order to insure 
efficacy in reducing mechanical allodynia in the mice with TIC injury, higher 
doses were administered to the animals than preferable. The only overt side 
effect that was observed was hypothermia when the animals were given the 300 
mg/kg dose of PIO. Since toxic doses of PIO are report to be >181 mg/kg, 
chronic feeding of mice at such high doses was not safe to perform. Therefore, it 
would be beneficial in future studies to observe chronic treatment of PIO in the 
mice with TIC injury at lower doses that have been previously published (Lee et 
al 2006; Morgenweck et al 2013; Takamura et al 1999). Morgenweck and 
colleagues (2013) pretreated their mice with PIO (10 mg/kg i.p. or 30 mg/kg p.o. 
twice daily) before the spared nerve injury and observed partial inhibition of 
mechanical allodynia (Morgenweck et al 2013). An additional experiment would 
be to modify the treatments in this study for chronic feeding. Instead of 
pretreating the mice with TIC with chronic low doses of PIO, treatment of PIO 
would start at least 8 weeks post injury. This would be a beneficial way to test 
PIO’s effects on mechanical allodynia in the mice with TIC after chronic 
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hypersensitivity and anxiety-like behaviors have already been established (see 
chapter 2).  Thereby, this study would answer the question as to whether PIO 
could be translatable to the clinic to attenuate pain in patients suffering with 
continuous trigeminal neuropathic pain.  
Furthermore, previous studies have speculated that by providing chronic 
treatment, PIO will act through PPARγ receptor signaling as a transcription factor 
thereby downregulating pro-inflammatory cytokines rather than acting through 
PPARγ receptor activated non-genomic pathways to reduce neurogenic 
inflammation (Fehrenbacher et al 2009; Feinstein et al 2005; Gardner et al 2005). 
Since PPARγ’s transcription actions takes longer than PPARγ’s rapid 
nongenomic actions, this leads to strong speculation that low doses will be more 
effective over a period of time rather acting rapidly as it did with the one-time 
dose given in this study.    
The histology done in this study was helpful not only to show localization 
of PPARγ immunoreactivity in the TBSNC, but also to demonstrate that PPARγ is 
upregulated three weeks after injury in the TBSNC. Future studies could observe 
the alteration of immunoreactivity of PPARγ at different time points after TIC 
injury such as 6, 9, 12 weeks post. This could be performed simultaneously with 
a double-labeling of cytokines (IL-6, TNF-α) as well as glial markers (IB-4, OX-
42). This would provide insight into the relationship that is possibly occurring 
between the neural immune system and the upregulation of PPARγ.  
For the DCS/PIO combined treatment study, one limitation is that only one 
drug dose combination was used (80 mg/kg DCS + 100 mg/kg PIO). Future 
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studies should be conducted at different dose combinations to determine if lower 
doses of both drugs would elicit a similar or more effective anti-allodynic effect. In 
this study, the mice with TIC were only given 7 days of DCS treatment and on the 
7th day received a bolus of PIO. It would be more interesting to determine if 
simultaneous chronic feeding of both DCS and PIO resulted in a greater increase 
in mechanical threshold. As stated above, a future study would be to determine 
an effective chronic treatment dose of PIO.  Once determined, the low dose of 
PIO and DCS could be given chronically together. Based on the data from the 
study in which the one-time low dose combination of DCS/PIO attenuated 
mechanical allodynia, speculation would lead to the theory that chronic treatment 
of even lower doses will elicit an effect over time. However, questions would 
arise of the mechanism: 1) Are the drugs acting through their receptors 
(DCSNMDAR and PIOPPARγ), 2) Are they acting through receptor 
independent pathways (mitochondrial actions), or more likely 3) Are they acting 
through both receptor dependent and independent pathways?  
This current study observed the receptor independent actions of the drug 
combinations and its effects on improving mitochondrial function after the TIC 
injury. Another limitation of this study is that only State III, State IV, and the RCR 
were conducted for mitochondrial dysfunction in the Seahorse assay.  
Alternatively, future studies could determine specifically if complex I is 
dysfunctional by measuring the NADH/NAD+ ratio before and after  nerve injury. 
Since complex I is important for State III and State IV electron transport 
respiration, this would be a beneficial experiment to run in order to determine if 
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the mitochondrial dysfunction that is observed is due to alteration of the complex 
I redox state (Pandya et al 2013; Sauerbeck et al 2011a). Furthermore, the 
activity of the remaining complexes in the mETC could be observed in future 
studies using the Oxytherm method to determine if one or more complex is 
responsible for the mitochondrial dysfunction that occurs after TIC injury in the 
mitochondrial cortex (Mustafa et al 2010; Sullivan et al 2004b).  
Since there are no changes observed in the calcium dynamics of the 
isolated mitochondria (cortex and brainstem), measuring total oxidative stress 
could also provide explanation for the mitochondrial dysfunction observed. By 
measuring reactive oxygen/nitrogen species using spectrophotometric assays 
along with the H2O2 production (Sullivan et al 2004b), we could not only 
determine if oxidative stress is occurring in the mitochondria, but what particular 
oxidative stress species is responsible. Taken together with the experiments 
listed above, a mechanism for mitochondrial dysfunction could be deduced.  
Furthermore, future studies could determine more specifically how the 
DCS/PIO drug combination is acting  on the mitochondria to reverse dysfunction. 
It could be from any of the mechanisms listed above and should be studied in 
more detailed. Future studies could analyze the cortical mitochondria from the 
mice with TIC treated with chronic feeding of the DCS/PIO combination to 
observe if there is greater reversal of mitochondrial dysfunction.  
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5.5. Significance and Innovation  
Overall, these studies advanced the field of orofacial pain by providing:  
1) Detail characterization of a novel model useful as a tool in identifying 
molecular targets that play a major role in the etiology and 
maintenance of trigeminal neuropathic pain. 
2) First report that identifies upregulated PPARγ in the TBSNC after 
injury.  
3) First report that PIO attenuates trigeminal neuropathic pain through 
activation of PPARγ receptor signaling. 
4)  First report that the DCS/PIO combination attenuates trigeminal pain 
as well as anxiety related to pain. 
5) First demonstration that mitochondrial dysfunction occurs in the cortex 
of the mice after TIC injury and that this dysfunction can be improved 
by the DCS/PIO combination.  
 
 The characterization of the TIC injury model is an advancement in the field 
of trigeminal pain research because orofacial pain mouse models previously 
described do not have characteristics as closely matching those of patients with 
chronic facial neuropathic pain (Bornhof et al 2011; Luccarini et al 2006). Since 
this model has stronger translational features than the other models display, the 
TIC injury model can be used to study pharmaceutical agents that perhaps can 
help relieve facial pain and anxiety-related to pain. Finally, since this model is 
induced in mice, the model could be used for genetic studies of trigeminal 
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neuropathic pain. Developing specific gene knockout mice will be helpful in 
determining other molecular targets that are important in the etiology and 
maintenance of trigeminal neuropathic pain. 
 These studies will be useful when treating orofacial pain patients in the 
future. By determining that PPARγ is a molecular target and that PPARγ 
activation will attenuate trigeminal pain, the potential exists to repurpose the FDA 
approved diabetic therapeutic drug, PIO. It is true that caveats exist when 
discussing the possibility of using PIO as a chronic therapeutic option. Currently, 
PIO has been withdrawn from the market in Germany and France due to 
increased health factors including bladder cancer, edema, and cardiac issues 
(Kostapanos et al 2013). However, it is important to mention that clinical and 
animal studies performed in non-diabetic subjects that were given chronic 
treatments of PIO did not suffer from the same side effects (i.e. no change in LDL 
levels and no overt signs of edema and cardiac risk) (Aithal et al 2008; Fullert et 
al 2002; Szapary et al 2006). This leads to strong speculation that PIO may not, 
in fact, be as toxic in patients who suffer from a metabolic disorder.  
Furthermore, although the doses that were used in this study were high, 
when comparing the mouse doses to human doses, they were in normal range 
prescribed for patients. Clinical dose for PIO ranges from 15 mg/kg to 45 mg/kg / 
day. Shaw and colleagues determined a relatable equation factoring the body 
weight and surface area of an average mouse and human that better estimates 
that the 300 mg/kg PIO dose in mice is equivalent to about 25 mg/kg PIO for a 
human(Reagan-Shaw et al 2008). Therefore, this highest dose given to the mice 
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in this study, falls within normal dosage range for humans. Whether this dose will 
be efficacious in treatment of the pain that is suffered by patients with chronic 
orofacial pain will need to be determined. Furthermore, although DCS is being 
tested for the treatment of sciatic pain and the anxiety-related to pain in humans 
(Davis et al 2006; Millecamps et al 2007; Norberg et al 2008), this data support 
the repurposing of DCS for the treatment of trigeminal neuropathic pain, 
specifically in combination with PIO.   
Furthermore, new drug therapies/deliveries can be challenged. For 
example, a clinical trial could be conducted with the combination of both 
DCS/PIO could determine an effective dose combination that would reduce the 
side effects of PIO while potentiating the inhibitory effect on neuropathic pain and 
the anxiety-related to pain. Many patients will often receive high doses of 
medication, or sometimes two pills, an analgesic and an anti-depressant drug 
(De Leeuw 2008; Zakrzewska 2013). However, this study determines that 
combination of the two, as a double edged sword, act as both an analgesic and 
anti-depressant (see chapter 4).  
The two drugs together could propel the chronic pain field forward for many 
reasons. One being it challenges the way the clinicians, basic scientists, and 
industry drug developers think about old drugs. If there is a way to save money 
by utilizing available drugs, that not only attenuate pain, but together have a 
potentiated effect, then the money invested in drug development could be better 
spent and discovery shifted into drug repurposing. This will save time and money 
in the long run while treating patients more quickly. Furthermore, the present 
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study supports dual therapy treatment. Recent studies have observed the 
synergistic effects of PIO with pravastatin to decrease inflammation  (Wei et al 
2007) as well as the synergistic effects of DCS and valproic acid for the 
extinction of fear (Kuriyama et al 2011).  
Finally, this was the first study to determine that mitochondrial dysfunction 
is a key play in trigeminal neuropathic pain, highlighting the mitochondria also is 
a drug target for treating facial pain. This study also determined ex vivo that the 
combination of DCS/PIO is acting independently of their known receptors to 
improve mitochondrial dysfunction. Studies have linked mitochondrial dysfunction 
to neuronal injury and neuropathy (Bouillot et al 2002; Ferrari & Levine 2010; 
Joseph et al 2004; Joseph & Levine 2006; Kim et al 2004; Pandya et al 2007; 
Park et al 2006; Schwartz et al 2009; Shin et al 2003; Sui et al 2013; Sullivan et 
al 2007), and others to depression (Gardner & Boles 2008; Kato 2011; Kato & 
Kato 2000; Rezin et al 2009). This was the first study to determine that a drug 
combination targeting mitochondria can in fact attenuate both of these aspects of 
pain in vivo. Perhaps these studies will not only encourage a more in depth study 
of mitochondria and its link to trigeminal neuropathic pain, but also that the drug 
combination itself can be utilized in so many different diseases related to 
mitochondrial dysfunction. This suggests other drugs that target the improvement 
of mitochondrial dysfunction could be utilized. Future studies need to be 
conducted to confirm the specific pathway(s) that DCS/PIO are utilizing to elicit 
these effects.  
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5.6. Conclusion 
This study was successful in characterizing a novel orofacial neuropathic 
pain mouse model, TIC, and determining the usefulness of the similarities it has 
with the clinical syndrome of continuous trigeminal neuropathic pain. This study 
supports the repurposing of PIO and DCS as useful pharmaceuticals in treating 
trigeminal neuropathic pain, particularly in a low dose combination by acting to 
improve mitochondrial dysfunction. Overall, this study accentuates the need for 
new pharmaceutical treatments for patients suffering with trigeminal pain and 
provides two novel molecular targets (PPARγ and mitochondria) as options to 
attenuate continuous trigeminal neuropathic pain.   
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Appendix 1.  Abbreviations 
AAALAC Association for Assessment and Accreditation of 
Laboratory Animal Care International  
AAPM    the American Academy of Pain Medicine 
ACC    Cingulate cortex 
ADP    Adenosine diphosphate    
ANOVA   Analysis of variance  
ATPase   Adenylpyrophosphatase 
BOLD    Blood-oxygen-level dependent    
CCI-ION   Chronic constriction injury of the infraortibal nerve 
CBT    Cognitive behavioral therapy 
2,4-DNP   2,4-Dinitrophenol  
DCS    D-cycloserine  
DMSO    Dimethyl sulfoxide  
EDP     an energy-dissipating pathway  
EGTA    Ethylene glycol tetraacetic acid    
FDA    Food and Drug Administration 
FCCP     Trifluorocarbonylcyanide Phenylhydrazone 
fMRI     Functional magnetic resonance imaging 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IASP    the International Association for the Study of Pain 
ION The infraortibal nerve 
IACUC   Institutional Animal Care and Use Committee  
136 
 
i.p.    Intraperitoneal  
IL-6     Interleukin 6 
mETC    the mitochondrial electron transport chain  
MIB    Mitochondrial isolation buffer  
MRB     Mitochondrial running buffer 
NF-κB Nuclear factor kappa-light-chain-enhancer of 
activated B cells 
NMDA   N-Methyl-D-aspartate 
NIH    National Institute of Health  
OCR    Oxygen Consumption Ratio  
PAG    Periaqueductal gray  
pCCI-ION Partial chronic constriction injury of the infraortibal 
nerve 
PFC     Prefrontal cortex 
PIO    Pioglitazone 
P.O.    per os 
PMF    Proton motive force  
PPAR-α   Peroxisome proliferator-activated receptor alpha 
PPAR-β/δ Peroxisome proliferator-activated receptor beta/delta 
PPARγ Peroxisome proliferator-activated receptor gamma 
PPRE  Peroxisome proliferator-activated receptor response 
elements  
PPC    posterior parietal cortex   
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ROS    Reactive oxygen species 
RCR     the Respiratory Control Ratio  
RXR     Retinoid X receptor  
S1/S2    Somatosensory cortex 1 and 2 
SMA    Insula cortex, supplementary motor area 
S.C.    Subcutaneous     
TBSNC    Trigeminal brainstem sensory nuclear complex  
TIC    Trigeminal Inflammatory Compression  
TNF-α    Tumor necrosis factor alpha  
TZD    Thiazolidinedione  
USDA     the United States Department of Agriculture  
VPM    Ventroposteromedial nucleus of the thalamus 
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Competition. Conference of Southern Graduate Schools. San Antonio, Texas, 
2014.  
Podium Presentation. “Determine the efficacy and safety of pharmacological 
treatments for novel models of orofacial neuropathic pain.” COBRE Review 
Board, University of Kentucky, 2014.  
Workshop, “Elevator Pitches,” Chalk Talks, Physiology Department, University 
of Kentucky, February 2014. 
Podium Presentation.. Stopping Orofacial Pain. Three Minute Thesis 
Competition. University of Kentucky, 2013.  
Podium Presentation. “Stopping the TIC: Alleviating Trigeminal Neuropathic 
Pain Using PPAR Agonists.” Physiology Departmental Seminar, University of 
Kentucky, 2013.  
Guest Speaker “Graduate Research at University of Kentucky.” Asbury 
University, Wilmore Ky.  April 2013,2014. 
 
PROFESSIONAL AFFILIATIONS 
 
Society for Neuroscience, April 2014-Present 
Bluegrass American Physiology Society, March 2014-Present 
 
TEACHING EXPERIENCE 
 
University of Kentucky, Lexington, KY  
Teaching Assistant, Department of Physiology, PGY 207 
Asbury University, Wilmore, KY      
Guest Lecturer, BIO 352: Human Physiology 
 
COMMUNITY SERVICE 
Lexington Medical/Dental Refuge Clinic 
Southland Christian Church 
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